Introduction {#s1}
============

The majority of new HIV-1 infections are transmitted via sexual intercourse, and semen is the main vector for viral spread. Far from being a passive vehicle, semen potently enhances HIV infectivity ([@bib49]; [@bib28]). This HIV-enhancing activity is attributed to seminal amyloid fibrils ([@bib49]; [@bib28]; [@bib67]; [@bib81]) that form by self-assembly of proteolytic fragments of prostatic acid phosphatase (PAP248-286 and PAP85-120) and the homologous proteins semenogelin 1 (SEM1) and semenogelin 2 (SEM2) ([@bib49]; [@bib67]; [@bib3]; [@bib9]; [@bib51]). Seminal amyloid fibrils are highly cationic, and the positively charged fibrils capture HIV virions, increase viral attachment rates to target cells, and augment fusion ([@bib69]; [@bib3]; [@bib81]). By doing so, fibrils promote HIV infection in vitro by several orders of magnitude, whereas the corresponding monomeric peptides have no effect ([@bib49]; [@bib67]; [@bib3]). Importantly, the stimulatory effect of seminal amyloid is the greatest at low virus concentrations ([@bib49]), and semen and PAP248-286 fibrils (termed SEVI for Semen-derived Enhancer of Virus Infection) may facilitate vaginal virus transmission after exposure to low viral doses ([@bib47]; [@bib53]; [@bib50]). HIV transmission rates are relatively low, occurring as infrequently as 1 in 200 to as low as 1 in 10,000 coital acts ([@bib21]). Thus, counteraction of infectivity promoting amyloids in semen should reduce or even prevent HIV transmission via the sexual route.

The lysine- and arginine-specific molecular tweezer, CLR01 ([Figure 1A,B](#fig1){ref-type="fig"}) ([@bib16]; [@bib29], [@bib31]), inhibits amyloid fibrillization by engaging specific lysine, arginine, or both residues within a variety of disease-associated amyloidogenic proteins including amyloid-β protein (Aβ), tau, islet amyloid polypeptide, transthyretin, and α-synuclein ([@bib75]; [@bib5]; [@bib64]; [@bib74]; [@bib1]; [@bib15]; [@bib37]; [@bib95]). Furthermore, CLR01 has even been found to slowly remodel preformed Aβ and α-synuclein fibrils over the course of several weeks ([@bib75]; [@bib64]). CLR01 binds lysine residues with a *K*~*d*~ of ∼10 µM and also binds arginine residues, albeit with ∼10-fold lower affinity ([@bib16]; [@bib13]). The unprecedented high specificity of CLR01 for basic amino acids relies on a unique binding mode in which the tweezer draws the cationic side chains into its torus-shaped cavity and engages the ammonium cation of lysine or the guanidinium cation of arginine with its anionic phosphate group in a tight ion pair ([Figure 1B](#fig1){ref-type="fig"}) ([@bib30]). No other amino acids fulfill the requirements for this threading mechanism. The structure of the CLR01-lysine complex and the precise mechanism of lysine threading into the CLR01 guest cavity and subsequent ion pairing have been extensively characterized by NMR spectroscopy, crystal structure, molecular dynamics, and quantum mechanics/molecular mechanics (QM/MM) calculations ([@bib6]; [@bib13]; [@bib30]). Importantly, CLR01 appears only to complex with readily accessible lysine or arginine residues on protein surfaces, as evidenced by crystal structures and NMR experiments ([@bib6]). This restriction makes CLR01 more selective for lysine or arginine residues found in intrinsically unfolded proteins or protein sequences.10.7554/eLife.05397.003Figure 1.CLR01 binds to lysine and arginine residues.(**A**) Chemical structures of CLR01 and CLR03. (**B**) Stick representation of the structures of CLR01 and CLR03 and their engagement of lysine side chains. (**C**--**E**) The primary sequences of PAP248-286 (**C**), PAP85-120 (**D**), and SEM1(45-107) (**E**) are provided. Lysine and arginine residues are in red and hexapeptides predicted to form steric zippers ([@bib20]; [@bib9]) are underlined. (**F**) The average structures of the most populated clusters derived from the REMD simulations of PAP248-286 (left), PAP248-286 with 7 CLR01 molecules (middle), and PAP248-286 with 8 CLR03 molecules (right) are shown in the upper row, CLR01 and CLR03 molecules are not shown for clarity. The lower row shows, for each case, a representative structure of the most populated cluster including CLR01 and CLR03. (**G**) CLR03 establishes only labile interactions with PAP248-286 as shown by the large X-P distances (Å) between one P atom of CLR03 and the nitrogen atom of the lysine side chain (or carbon atom of the guanidinium moiety of arginine). Contrarily, the complexes between CLR01 and Lys or Arg were conserved during all the REMD simulations.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.003](10.7554/eLife.05397.003)

Since amyloidogenic seminal peptides are particularly rich in lysine and arginine residues ([@bib69]; [@bib3]; [@bib9]) ([Figure 1C--E](#fig1){ref-type="fig"}, Lys and Arg residues are highlighted in red), we hypothesized that CLR01 might interfere with their HIV-enhancing activity. Here, we establish that CLR01 inhibits amyloidogenesis of PAP and SEM peptides, neutralizes the cationic surface charge of seminal amyloid, and rapidly remodels preformed SEVI and PAP85-120 fibrils. Strikingly, CLR01 also exhibits a direct antiviral effect by selectively disrupting the membrane of enveloped viruses. Thus, CLR01 represents an unprecedented candidate for further development as a microbicide as it not only inactivates HIV and other enveloped viruses but also antagonizes host-encoded seminal amyloids that enhance viral infection.

Results {#s2}
=======

CLR01 inhibits spontaneous assembly of seminal amyloid fibrils {#s2-1}
--------------------------------------------------------------

Lysine residues in PAP248-286, PAP85-120, SEM1, and SEM2 peptides are frequently found within or immediately adjacent to hexapeptides predicted to form self-complementary β-strands ([Figure 1C--E](#fig1){ref-type="fig"}, underlined residues), termed steric zippers, which often comprise the spine of amyloid fibrils ([@bib54]; [@bib20]; [@bib73]; [@bib9]; [@bib18]). Moreover, the wealth of basic residues in PAP248-286, PAP85-120, and SEM1(45-107) ([Figure 1C--E](#fig1){ref-type="fig"}) led us to hypothesize that the lysine- and arginine-specific tweezer, CLR01, but not its derivative CLR03, which lacks hydrophobic sidewalls ([@bib75]) ([Figure 1A,B](#fig1){ref-type="fig"}), might bind to these residues and interfere with fibril assembly. To test this hypothesis, we first performed replica exchange molecular dynamics simulations using the available structure of PAP248-286, the best characterized of the amyloid-forming peptides in semen ([@bib49]; [@bib9]; [@bib17]). This analysis revealed that in silico, CLR01 bound at least seven of the eight positively charged residues in PAP248-286 without grossly altering peptide secondary structure ([Figure 1F](#fig1){ref-type="fig"}). Indeed, CLR01 engaged Lys251, Lys253, Lys281, and Lys282 ([Figure 1F,G](#fig1){ref-type="fig"}), which all reside in predicted steric zippers ([@bib9]) ([Figure 1C](#fig1){ref-type="fig"}). Moreover, CLR01 bound Arg257, Lys281, and Lys282 ([Figure 1F,G](#fig1){ref-type="fig"}), which form part of the cross-β SEVI fibril core defined by hydrogen--deuterium exchange ([@bib17]). The CLR01 interaction was very similar among all the different lysine and arginine binding sites as indicated by similar (X-P) distances between the lysine ammonium or arginine guanidinium groups (X) and the bound phosphate group (P) in CLR01 ([Figure 1G](#fig1){ref-type="fig"}). By contrast, CLR03 only established more distant and variable interactions with lysine and arginine residues ([Figure 1G](#fig1){ref-type="fig"}). Thus, CLR01 but not CLR03 tightly shielded lysine and arginine residues in PAP248-286 suggesting that CLR01 could prevent PAP248-286 assembly into SEVI fibrils.

To test this prediction, CLR01 was assessed for its ability to inhibit the spontaneous amyloidogenesis (i.e., assembly in the absence of preformed fibril seeds) of PAP248-286, PAP85-120, and SEM1(45-107) ([@bib49]; [@bib67]; [@bib3]). Using the fluorescence of the diagnostic dye Thioflavin-T (ThT), which increases upon amyloid binding, we found that CLR01, but not CLR03, inhibited fibril assembly of all three peptides ([Figure 2A--C](#fig2){ref-type="fig"}). The half-maximal inhibitory concentrations (IC~50~) of CLR01 inhibition of PAP248-286 and SEM1(45-107) fibrillization were ∼1.19 µM and ∼16.2 µM, respectively ([Figure 2D,F](#fig2){ref-type="fig"}). The IC~50~ for inhibition of PAP248-286 fibrillization was significantly lower than the IC~50~ for inhibition of SEM1(45-107) fibrillization (one-way ANOVA, p \< 0.0001), suggesting that lysine, arginine, or both residues are more critical for PAP248-286 fibrillization. Moreover, inhibition of PAP248-286 and SEM1(45-107) fibrillization exhibited shallow dose--response curves with Hill slopes of ∼0.6 for PAP248-286 and ∼0.44 for SEM1(45-107) ([Figure 2D,F](#fig2){ref-type="fig"}), indicating negative co-operativity or CLR01 binding to multiple sites with different affinities. Importantly, these shallow dose responses provide evidence against a non-specific mechanism of inhibition involving colloidal CLR01 aggregates, as aggregating inhibitors tend to exhibit steep dose response curves ([@bib72]). The IC~50~ of CLR01 to impede PAP85-120 assembly was significantly higher at ∼228 µM (one-way ANOVA, p \< 0.0001; [Figure 2E](#fig2){ref-type="fig"}). The higher IC~50~ is likely due to the lower number of lysine or arginine residues in the PAP85-120 sequence located in hexapeptides predicted to have high amyloid propensity ([Figure 1D](#fig1){ref-type="fig"}) ([@bib9]). Indeed, PAP85-120 has 1 lysine or arginine located in predicted steric zippers, whereas PAP248-286 has 4 and SEM1(45-107) has 3 ([Figure 1D](#fig1){ref-type="fig"}). The Hill slope was ∼1.26, indicating weak positive co-operativity ([Figure 2E](#fig2){ref-type="fig"}), but was still below the ∼1.5--2 range that might indicate a mechanism of inhibition involving colloidal CLR01 aggregates ([@bib72]).10.7554/eLife.05397.004Figure 2.CLR01 inhibits formation of seminal amyloid fibrils.CLR01 inhibits fibril formation by PAP248-286 (1 mM) (**A**), PAP85-120 (1 mM) (**B**), and SEM1(45-107) (500 µM) (**C**). Peptides were incubated with equimolar CLR01, CLR03, or buffer and agitated at 1400 rpm at 37°C. Aliquots were removed at various time points and fibrillization was assessed using the amyloid-binding dye, Thioflavin-T (ThT). Values represent means ±SEM (n = 4 for PAP248-286; n = 3 for PAP85-120; n = 9 for SEM1(45-107)). Transmission electron microscopy (TEM) images of PAP248-286 (**A**), PAP85-120 (**B**), and SEM1(45-107) (**C**) agitated in the presence of CLR01, CLR03, or buffer. PAP248-286 and SEM1(45-107) samples were visualized after 72 hr of agitation, PAP85-120 after 24 hr. Scale bar: 500 nm. (**D**) Dose-response curve for CLR01 inhibition of PAP248-286 (1 mM) fibrillization after 72 hr of agitation. The IC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--12). (**E**) Dose-response curve for CLR01 inhibition of PAP85-120 (1 mM) fibrillization after 24 hr of agitation. The IC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--7). (**F**) Dose--response curve for CLR01 inhibition of SEM1(45-107) (500 µM) fibrillization after 72 hr of agitation. The IC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--12). (**G**, **H**) CLR01 is unable to block PAP248-286(Ala) fibrillization. Lyophilized PAP248-286(Ala) was dissolved in PBS (100 µM), incubated with CLR01 (100 µM), CLR03 (100 µM), or buffer and agitated at 1400 rpm at 37°C. Aliquots were removed at various time points and fibril assembly was assessed using ThT fluorescence (**G**) or sedimentation analysis (**H**). Values represent means ±SEM (n = 7--9) (**G**) or means ±SEM (n = 3) (**H**). (**I**) CLR01 is unable to block PAP85-120(Ala) fibrillization. Lyophilized PAP85-120(Ala) was dissolved in PBS (150 µM), incubated with CLR01 (150 µM), CLR03 (150 µM), or buffer and agitated at 1400 rpm at 37°C. At the indicated times, fibril assembly was assessed using ThT fluorescence. Values represent means ±SEM (n = 3). (**J**) Inhibition of seeded PAP248-286 fibrillization by CLR01. Lyophilized PAP248-286 peptide was reconstituted at 1 mM in PBS and incubated with 1 mM CLR01, 1 mM CLR03, or buffer. Preformed SEVI fibrils (2% wt/wt) were added to each condition and agitated at 1400 rpm at 37°C. Aliquots were removed at various time points and fibrillization was assessed using ThT fluorescence. Values represent means ±SEM (n = 6). (**K**) Electron microscopy visualization of CLR01 inhibition of seeded PAP248-286 fibrillization after 48 hr of agitation. Scale bar: 500 nm. (**L**) Dose-response curve for CLR01 inhibition of PAP248-286 fibrillization seeded by preformed SEVI fibrils (2% wt/wt) after 48 hr of agitation. The IC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--7).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.004](10.7554/eLife.05397.004)10.7554/eLife.05397.005Figure 2---figure supplement 1.CLR01 does not displace ThT from SEVI, PAP85-120, or SEM1(45-107) fibrils.Preformed SEVI, PAP85-120, or SEM1(45-107) fibrils (5 µM monomer) were preincubated with ThT (25 µM) for 30 min at room temperature. Buffer (PBS), CLR01 (250 µM), or a known competitor of ThT binding, BTA-1 (250 µM) were then added and incubated for 10 min at room temperature. ThT displacement was then assessed by fluorescence measurements. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer control to the CLR01 or BTA-1 condition (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.005](10.7554/eLife.05397.005)10.7554/eLife.05397.006Figure 2---figure supplement 2.CLR01 does not impede adsorption of SEVI, PAP85-120, or SEM1(45-107) fibrils to the EM grid.Preformed SEVI, PAP85-120 fibrils, or SEM1(45-107) fibrils (20 µM) were treated with a 10-fold excess of CLR01 or buffer for 10 min and processed for TEM. Note the presence of abundant fibrils under each condition indicating that CLR01 does not impede fibril adsorption to the EM grid.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.006](10.7554/eLife.05397.006)10.7554/eLife.05397.007Figure 2---figure supplement 3.Lysine and poly-L-lysine antagonize the ability of CLR01 to inhibit spontaneous formation of seminal amyloid fibrils.(**A**) PAP248-286 (1 mM) was incubated with buffer or CLR01 (100 µM) in the presence or absence of lysine (20 mM) or poly-L-lysine (1 mM) and agitated at 1400 rpm at 37°C for 68 hr. Fibrillization was assessed via ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001). (**B**) PAP248-286 (100 µM) was incubated with CLR01 (100 µM) or buffer in the presence or absence of lysine (20 mM) or poly-L-lysine (1 mM) and agitated at 1400 rpm at 37°C for 68 hr. Fibrillization was assessed via ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001). (**C**) SEM1(45-107) (0.5 mM) was incubated with CLR01 (100 µM) or buffer in the presence or absence of lysine (20 mM) or poly-L-lysine (1 mM) and agitated at 1400 rpm at 37°C for 68 hr. Fibrillization was assessed via ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.007](10.7554/eLife.05397.007)10.7554/eLife.05397.008Figure 2---figure supplement 4.BSA or preclearing CLR01 has no effect on the ability of CLR01 to inhibit formation of seminal amyloid fibrils.PAP248-286 (1 mM), PAP85-120 (1 mM), or SEM1(45-107) (500 µM) was incubated with CLR01 (1 mM) or buffer in the presence or absence of BSA (10 mg/ml) and agitated at 1400 rpm at 37°C for 68 hr. In some reactions, CLR01 was first cleared by centrifugation at 16,100×*g* for 20 min at 25°C (precleared). Fibrillization was assessed via ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.008](10.7554/eLife.05397.008)10.7554/eLife.05397.009Figure 2---figure supplement 5.Lysine or poly-L-lysine, but not BSA or preclearing CLR01 solutions, antagonize the ability of CLR01 to inhibit seeded assembly of SEVI fibrils.PAP248-286 (1 mM) was incubated with agitation at 37°C for 24 hr with preformed SEVI fibrils (2% wt/wt) plus CLR01 (100 µM) or buffer in the presence or absence of lysine (20 mM), poly-L-lysine (1 mM), or BSA (10 mg/ml). In some reactions, CLR01 was first cleared by centrifugation at 16,100×*g* for 20 min at 25°C (precleared). Fibrillization was assessed via ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.009](10.7554/eLife.05397.009)

We examined the possibility that CLR01 might simply displace ThT from fibrils by employing a ThT displacement assay ([@bib36]). Thus, preformed SEVI, PAP85-120, or SEM1(45-107) fibrils were preincubated with ThT. Buffer, or an excess of CLR01 or a known competitor of ThT binding, BTA-1, were then added and ThT displacement was assessed by fluorescence measurements ([@bib36]). ThT fluorescence decreased drastically in the presence of BTA-1, confirming its ability to displace ThT from fibrils ([@bib36]), whereas CLR01 and buffer had no effect ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These findings suggest that CLR01 does not simply displace ThT from SEVI, PAP85-120, or SEM1(45-107) fibrils. Thus, any reduction in ThT fluorescence caused by CLR01 can be attributed to an inhibition of fibril assembly.

Transmission electron microscopy (TEM) analysis confirmed that CLR01 prevented assembly of PAP248-286 and SEM1(45-107) into mature fibrils ([Figure 2A,C](#fig2){ref-type="fig"}). Only small oligomeric forms ([Figure 2A](#fig2){ref-type="fig"}) or amorphous aggregates in combination with sparse short fibrils ([Figure 2C](#fig2){ref-type="fig"}) were detectable in the presence of CLR01, as opposed to abundant fibrils observed in the presence of buffer or CLR03 ([Figure 2A,C](#fig2){ref-type="fig"}). The effect of CLR01 on PAP85-120 assembly was less apparent by TEM ([Figure 2B](#fig2){ref-type="fig"}). However, the PAP85-120 assemblies formed in the presence of CLR01 appeared more flexible and curvilinear, and differed from the rigid, straight fibrils formed in the presence of CLR03 or buffer ([Figure 2B](#fig2){ref-type="fig"}). Since the structures that formed in the presence of CLR01 were not ThT-reactive ([Figure 2B](#fig2){ref-type="fig"}) they most likely represent non-amyloid aggregates. Thus, CLR01 appears to impede the transition of PAP85-120 to mature amyloid fibrils and abrogates formation of SEVI and SEM1(45-107) fibrils.

We excluded the possibility that CLR01 might impede adsorption of SEVI, PAP85-120, or SEM(45-107) fibrils to the EM grid. When we mixed CLR01 (or buffer) with preformed SEVI, PAP85-120, or SEM1(45-107) fibrils for 10 min (a time at which no fibril remodeling occurs; [Figure 3A--C](#fig3){ref-type="fig"}) and then adsorbed them to the grid, we observed abundant fibrils in both the CLR01 and buffer control conditions ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Thus, any reduction in the presence of fibrils observed by EM can be attributed to inhibition of fibril assembly.10.7554/eLife.05397.010Figure 3.CLR01 rapidly remodels SEVI and PAP85-120 fibrils.(**A**--**C**) Preformed SEVI fibrils (**A**), PAP85-120 fibrils (**B**), and SEM1(45-107) fibrils (**C**) (20 µM) were treated with a 10-fold excess of CLR01 or CLR03 or buffer for 0--6 hr at 37°C. Fibril integrity was assessed using ThT. Values represent means ±SEM (n = 3). TEM (middle panel) and confocal microscopy (bottom panel) of SEVI (**A**), PAP85-120 fibrils (**B**), and SEM1(45-107) fibrils (**C**) obtained after 2 hr treatment with CLR01, CLR03, or buffer. Scale bar for TEM images: 500 nm. For confocal microcopy (CoM), samples were stained with Proteostat dye. Scale bar: 20 µm. (**D**) CD spectrum of 50 µM SEVI fibrils incubated with 50 µM CLR01, 50 µM CLR03, or buffer. A representative spectrum is shown. (**E**) The mean residue ellipticity (MRE) at 218 nm was averaged from three independent experiments. Values represent means ±SEM. (**F**) Seeding with CLR01-remodeled SEVI products. SEVI fibrils (20 µM) were treated with 200 µM CLR01, 200 µM CLR03, or buffer for 3 hr and reaction products were used to seed PAP248-286 fibrillization (0.1% fibril seed, 1 mM peptide). Buffer conditions with no fibril seed present were also included. Fibrillization was monitored by ThT fluorescence. Values represent means ±SEM (n = 8). (**G**) Dose--response curve for CLR01 remodeling of SEVI fibrils (20 µM) after 2 hr of treatment. The EC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--15). (**H**) Dose-response curve for CLR01 remodeling of PAP85-120 fibrils (20 µM) after 2 hr of treatment. The EC~50~ value and Hill slope are indicated. Values represent means ±SEM (n = 3--14). (**I**) CLR01 is unable to remodel SEVI(Ala) fibrils. Preformed SEVI(Ala) fibrils (20 µM) were treated with 200 µM CLR01, 200 µM CLR03, or buffer for 0--6 hr. Fibril integrity was assessed using ThT fluorescence. Values represent means ±SEM (n = 3). (**J**) CD spectrum of 50 µM SEVI(Ala) fibrils incubated with either 50 µM CLR01, 50 µM CLR03, or buffer. One representative example is shown. (**K**) The mean residue ellipticity (MRE) at 218 nm was averaged from three independent experiments. Values represent means ±SEM (n = 3). (**L**) Preformed PAP85-120(Ala) fibrils (20 μM) were treated with CLR01 or CLR03 (200 μM) or buffer for 0--6 hr. Fibril integrity was assessed using ThT fluorescence. Values represent means ±SEM (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.010](10.7554/eLife.05397.010)10.7554/eLife.05397.011Figure 3---figure supplement 1.Lysine and poly-L-lysine antagonize the ability of CLR01 to remodel SEVI and PAP85-120 fibrils.SEVI (left) or PAP85-120 fibrils (right, 20 µM monomer) were treated with buffer or CLR01 (100 µM) in the presence or absence of lysine (20 mM) or poly-L-lysine (1 mM) for 2 hr at 37°C. Fibril remodeling was then assessed by ThT fluorescence. Values represent means ±SEM (n = 3--8). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.011](10.7554/eLife.05397.011)10.7554/eLife.05397.012Figure 3---figure supplement 2.BSA or preclearing CLR01 has no effect on the ability of CLR01 to remodel SEVI and PAP85-120 fibrils.SEVI (left) or PAP85-120 fibrils (right, 20 µM monomer) were treated with buffer or CLR01 (100 µM) in the presence or absence of BSA (10 mg/ml) for 2 hr at 37°C. In some reactions, CLR01 was first cleared by centrifugation at 16,100×*g* for 20 min at 25°C (precleared). Fibril remodeling was then assessed by ThT fluorescence. Values represent means ±SEM (n = 3). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (\*\*\* denotes p \< 0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.012](10.7554/eLife.05397.012)

To investigate the role of lysine and arginine interactions with CLR01 in the inhibition of fibril assembly, we examined PAP248-286(Ala) or PAP85-120(Ala), two peptide analogues in which all lysine and arginine residues are replaced by alanine ([@bib69]). PAP248-286(Ala) formed amyloid fibrils in the presence of CLR01, CLR03, and buffer ([Figure 2G](#fig2){ref-type="fig"}). To further analyze the effect of CLR01 on PAP248-286(Ala) assembly, we employed a sedimentation assay. This assay revealed that equal amounts of PAP248-286(Ala) entered the pellet fraction when the peptide was incubated with buffer or CLR01, indicating that the formation of PAP248-286(Ala) amyloid fibrils is unaffected by CLR01 treatment ([Figure 2H](#fig2){ref-type="fig"}). Thus, it is likely that in the presence of CLR01, PAP248-286(Ala) assembles into a subtly distinct set of cross-beta structures or fibril 'strains' that are less ThT-reactive ([Figure 2G,H](#fig2){ref-type="fig"}). Amyloidogenesis by PAP85-120(Ala) was also unaffected by CLR01 ([Figure 2I](#fig2){ref-type="fig"}). The PAP248-286(Ala) and PAP85-120(Ala) peptides spontaneously assemble into amyloid more rapidly than the wild-type peptides ([Figure 2A,B,G,I](#fig2){ref-type="fig"}). However, we have been unable to establish conditions (e.g., higher CLR01 concentrations) where CLR01 prevents assembly of PAP248-286(Ala) and PAP85-120(Ala) into amyloid fibrils (data not shown). These findings suggest that CLR01-lysine contacts, CLR01-arginine contacts, or both, are essential for inhibition of fibrillization.

Next, we tested if an excess of free lysine or poly-L-lysine could interfere with the ability of CLR01 to block fibrillization of PAP248-286, PAP85-120, and SEM1(45-107) ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Both 20 mM lysine and 1 mM poly-L-lysine completely abrogated CLR01 inhibition of fibril formation by these three peptides. These results strongly support direct interaction of the tweezer with lysine, arginine, or both residues in PAP248-286, PAP85-120, and SEM1(45-107) as the underlying mechanism of CLR01 inhibition. We suggest that these specific interactions preclude the conformational rearrangements necessary for amyloidogenesis.

Some small molecules must form higher order colloidal aggregates to inhibit amyloid assembly ([@bib14]; [@bib94]). BSA inhibits the activity of colloidal small-molecule aggregates via adsorption ([@bib43]; [@bib11]; [@bib14]). Additionally, colloidal small-molecule aggregates can be precleared via centrifugation ([@bib44]). Thus, we used these two techniques to test whether inhibition of PAP248-286, PAP85-120, or SEM1(45-107) aggregation could be mediated via unexpected colloid formation by CLR01. CLR01 was found to inhibit PAP248-286, PAP85-120, and SEM1(45-107) fibril assembly in the presence of BSA (10 mg/ml) or when solutions containing CLR01 were centrifuged at 16,100×*g* for 20 min before adding the supernatant solution to the proteins ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). Thus, CLR01 is not inhibiting PAP248-286, PAP85-120, and SEM1(45-107) fibril assembly via a mechanism that involves colloidal CLR01 aggregates.

CLR01 inhibits assembly of SEVI seeded by preformed fibrils {#s2-2}
-----------------------------------------------------------

The addition of a small amount of preformed SEVI fibrils to soluble PAP248-286 seeds polymerization and eliminates the lag phase for assembly ([@bib92]) (compare [Figure 2A](#fig2){ref-type="fig"} with [Figure 2J](#fig2){ref-type="fig"}). Remarkably, in addition to obstructing unseeded PAP248-286 assembly ([Figure 2A](#fig2){ref-type="fig"}), CLR01 also completely inhibited seeded fibrillization ([Figure 2J,K](#fig2){ref-type="fig"}). Dose--response analysis established an IC~50~ of ∼15.3 µM for CLR01 inhibition of seeded PAP248-286 assembly ([Figure 2L](#fig2){ref-type="fig"}) compared to ∼1.19 µM for spontaneous PAP248-286 assembly ([Figure 2D](#fig2){ref-type="fig"}). Thus, higher concentrations of CLR01 are required to inhibit PAP248-286 assembly once SEVI fibrils have formed. Interestingly, the Hill slope for inhibition of seeded PAP248-286 assembly was ∼3.1 indicating positive co-operativity and was steeper than the Hill slope of ∼0.6 for inhibition of spontaneous PAP248-286 fibrillization ([Figure 2D,L](#fig2){ref-type="fig"}). This dissimilarity might indicate a mechanistic difference in how CLR01 inhibits seeded and spontaneous PAP248-286 fibrillization. However, this difference is not likely to be due colloidal CLR01 aggregates, as inhibition of seeded assembly by CLR01 was unaffected by BSA or by preclearing CLR01 solutions via centrifugation ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). Rather, we suggest that the CLR01-mediated inhibition of fibril elongation in seeded SEVI assembly has requirements distinct from the CLR01-mediated inhibition of initial fibril nucleation in spontaneous, unseeded SEVI assembly.

Inhibition of seeded PAP248-286 assembly was alleviated by excess lysine or poly-L-lysine ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). Thus, inhibition of seeded PAP248-286 assembly by CLR01 likely requires specific interaction with lysine, arginine, or both residues. Importantly, because CLR01 impedes both unseeded and seeded PAP248-286 assembly, it likely acts at multiple stages of the fibrillization process including the initial nucleation and fibril elongation steps. These observations also indicate that lysine, arginine, or both residues play an important role in the primary nucleation and subsequent elongation of PAP248--286 fibrils.

CLR01 remodels preformed SEVI and PAP85-120 fibrils {#s2-3}
---------------------------------------------------

Semen-derived fibrils are abundant in liquefied fresh ejaculates ([@bib81]). Thus, agents that not only inhibit fibril formation but also remodel preformed fibrils would be advantageous for microbicide development ([@bib9]). To test whether CLR01 could remodel seminal amyloid, SEVI, PAP85-120 and SEM1(45-107) fibrils were treated with CLR01 or CLR03, and ThT fluorescence intensity was monitored. Brief incubations with CLR01 (10--20 min) had no effect, indicating that CLR01 did not simply displace ThT from fibrils ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [Figure 3A--C](#fig3){ref-type="fig"}). After 2 hr, however, CLR01 treatment of SEVI ([Figure 3A](#fig3){ref-type="fig"}) and PAP85-120 ([Figure 3B](#fig3){ref-type="fig"}) but not SEM1(45-107) ([Figure 3C](#fig3){ref-type="fig"}) fibrils resulted in a reduction in ThT fluorescence intensity by more than 50%. Even after 24 hr, SEM1(45-107) fibrils were not remodeled by CLR01 (data not shown). SEVI and PAP85-120 fibril remodeling was confirmed by TEM, which showed few intact fibrils and predominately smaller nonfibrillar species after CLR01 treatment ([Figure 3A,B](#fig3){ref-type="fig"}). By contrast, TEM revealed that SEM1(45-107) fibrils were still abundant after prolonged CLR01 treatment ([Figure 3C](#fig3){ref-type="fig"}). This observation confirms that CLR01 does not simply prevent fibrils from adsorbing to the EM grid ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Similar results were obtained by fluorescence microscopy (CoM) of samples stained with Proteostat, a red fluorescent aggregate sensing dye ([Figure 3A--C](#fig3){ref-type="fig"}) ([@bib81]). These effects of CLR01 were remarkably rapid in comparison to the slow disassembly of Aβ or α-synuclein fibrils by CLR01, which required several weeks ([@bib75]; [@bib64]). Thus, CLR01 can remodel SEVI and PAP85-120 fibrils on a time scale that would be useful for prevention of HIV infection, which usually takes place within the first hours after deposition of semen in the anogenital tract ([@bib71]).

We next performed circular dichroism experiments to examine the effect of CLR01 on the amyloid cross-β structure. Untreated SEVI fibrils or SEVI fibrils treated with CLR03 exhibited a pronounced minimum indicative of a characteristic β-sheet rich structure ([Figure 3D,E](#fig3){ref-type="fig"}). By contrast, SEVI fibrils incubated with CLR01 showed a loss in the β-sheet minimum ([Figure 3D,E](#fig3){ref-type="fig"}), confirming that CLR01 alters the cross-β architecture of SEVI fibrils. Furthermore, SEVI fibrils remodeled by CLR01 were less effective seeds for polymerization of monomeric PAP248-286 ([Figure 3F](#fig3){ref-type="fig"}). Thus, CLR01 remodels SEVI fibrils into alternative non-templating conformers.

A dose--response curve for CLR01-mediated remodeling of SEVI and PAP85-120 fibrils revealed a half-maximal effective concentration (EC~50~) value of ∼0.89 µM and ∼1.41 µM, respectively ([Figure 3G,H](#fig3){ref-type="fig"}). Interestingly, in both cases the Hill slope was similar, approximately −0.6 for SEVI and approimately −0.726 for PAP85-120, indicating negative co-operativity or CLR01 binding to multiple sites with different affinities. These shallow dose--response curves provide evidence against a colloidal mechanism of CLR01 action ([@bib72]). Previous studies have reported that a 10-fold molar excess of CLR01 could remodel preformed Aβ40, Aβ42, or α-synuclein fibrils slowly over a time period of weeks ([@bib75]; [@bib64]). It is therefore remarkable that CLR01 remodels SEVI and PAP85-120 fibrils with such alacrity and at sub-stoichiometric concentrations (relative to peptide monomers).

To elucidate the role of lysine- and arginine-tweezer interactions in CLR01-mediated remodeling of SEVI and PAP85-120 fibrils, experiments were performed with fibrils comprised of PAP248-286(Ala) or PAP85-120(Ala). CLR01 was unable to remodel preformed SEVI(Ala) or PAP85-120(Ala) fibrils ([Figure 3I--L](#fig3){ref-type="fig"}). Indeed, we have been unable to establish conditions (e.g., higher CLR01 concentrations) where CLR01 remodels SEVI(Ala) or PAP85-120(Ala) fibrils (data not shown). Furthermore, addition of excess free lysine or poly-L-lysine to CLR01 prevented its SEVI and PAP85-120 amyloid-remodeling activity ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Thus, CLR01-lysine, CLR01-arginine, or both contacts are critical for the remodeling process. By contrast, CLR01 retained SEVI and PAP85-120 amyloid-remodeling activity in the presence of BSA (10 mg/ml) or if CLR01 solutions were precleared via centrifugation ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Thus, colloidal CLR01 aggregates do not contribute to the amyloid-remodeling activity of CLR01. Taken together, our findings suggest that the lysine- and arginine-specific molecular tweezer CLR01 prevents formation of seminal amyloid and remodels mature PAP85-120 and SEVI fibrils via binding to lysine and arginine residues.

CLR01 abrogates the interaction of seminal amyloids with viral particles and diminishes their infection enhancing property {#s2-4}
--------------------------------------------------------------------------------------------------------------------------

Since the infectivity-enhancing activity of seminal amyloid fibrils is due to their positive surface charge ([@bib69]; [@bib3]), we examined next whether CLR01 affected this property. To prevent fibril remodeling from occurring in these experiments, fibrils were mixed with CLR01, CLR03, or buffer, and samples were immediately centrifuged to remove unbound CLR01 and CLR03 molecules. Subsequently, the surface charge of resuspended fibrils was determined by zeta potential measurements. We found that CLR01, but not CLR03, neutralized the positive surface charge of SEVI, PAP85-120, and SEM1(49-107) fibrils within minutes ([Figure 4A](#fig4){ref-type="fig"}). Notably, pre-treatment of CLR01 with lysine or poly-L-lysine abrogated the fibril neutralizing activity of CLR01 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), which further supports previous findings concerning the specificity underlying these interactions ([@bib16]; [@bib29], [@bib31]). Next, confocal microscopy was used to assess whether this neutralization could abrogate fibril binding to YFP-tagged virions. As previously shown ([@bib67]; [@bib3]; [@bib93]), buffer-treated fibrils efficiently sequestered virions ([Figure 4B](#fig4){ref-type="fig"}). In contrast, fibrils pretreated with CLR01, but not CLR03, were unable to form fibril--virion complexes ([Figure 4B](#fig4){ref-type="fig"}).10.7554/eLife.05397.013Figure 4.CLR01 neutralizes the positive surface charge of seminal amyloids and abrogates their ability to bind virions and enhance HIV infection.(**A**) Surface charge of seminal amyloids determined by zeta potential measurements. Fibrils were mixed with buffer, CLR01, or CLR03 and centrifuged for 10 min at 20,000×*g*. The pellets were resuspended in 1 mM KCl and zeta potential was measured. Values represent means ±SD (n = 3). (**B**) Fibrils (200 µg/ml) were pretreated with PBS, CLR01, or CLR03 in 20-fold excess for 5 min and stained with Proteostat dye. MLV-Gag-YFP particles (green) were added 1:2 and allowed to incubate with pretreated fibrils (red) for 5 min. Samples were analyzed using confocal microscopy. Scale bar: 5 µm. (**C**) CLR01 displaces virions from fibrils. MLV-Gag-YFP particles (green) were incubated with Proteostat-stained seminal amyloids (red) for 5 min. PBS, CLR01, or CLR03 were added at 20-fold excess, and after an additional 5 min of incubation, samples were analyzed by confocal microscopy. Scale bar: 5 µm. (**D**) CLR01 does not quench the fluorescence signal of MLV-Gag-YFP particles. MLV-Gag-YFP particles were treated with 300 µM CLR01 or CLR03 for 30 min at 37°C. Thereafter, virions were recovered in the pellet fraction via high-speed centrifugation and aliquots analyzed by confocal microscopy. Scale bar = 20 µm. (**E**) CLR01 antagonizes the HIV-1 enhancing activity of seminal amyloids. SEVI, PAP85-120, and SEM1(49-107) fibrils were mixed with a 20-fold excess of CLR01 or CLR03. CCR5-tropic HIV-1 was added and samples were used to inoculate TZM-bl cells. Infection rates were determined 3 days post infection. Values represent mean β-galactosidase activities derived from triplicate infections ±SD (RLU/s: relative light units per second). Numbers above symbols indicate the n-fold enhancement of infection.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.013](10.7554/eLife.05397.013)10.7554/eLife.05397.014Figure 4---figure supplement 1.Lysine and poly-L-lysine dose-dependently antagonize CLR01 binding to SEVI.SEVI fibrils were mixed with CLR01 and increasing amounts of lysine (1, 10 and 100-fold excess over CLR01) or poly-L-lysine (0.02, 0.25 and 2.5-fold excess of lysine monomer equivalents over CLR01) and centrifuged for 10 min at 20,000×*g*. The pellets were resuspended in 1 mM KCl and zeta potential was measured. Values represent means ±SD (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.014](10.7554/eLife.05397.014)10.7554/eLife.05397.015Figure 4---figure supplement 2.CLR01 does not quench the fluorescence signal of MLV-Gag-YFP particles.MLV-Gag-YFP particles were treated with 300 µM CLR01 or CLR03 for 30 min at 37°C. Thereafter, virions were recovered in the pellet fraction via high-speed centrifugation and aliquots analyzed by confocal microscopy. Z-stack images of the samples revealed a similar amount of fluorescent particles after treatment with CLR01 or CLR03 but altered distribution in the slides.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.015](10.7554/eLife.05397.015)10.7554/eLife.05397.016Figure 4---figure supplement 3.CLR01 is not cytotoxic.TZM-bl cells were incubated for 3 days with the indicated concentrations of (**A**) CLR01 and CLR03 and (**B**) CLR01, nonoxynol 9 (N9), sodium dodecyl sulfate (SDS) and Triton X-100 (TX-100). Cell viability was measured in an MTT assay. Values represent means ±SD (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.016](10.7554/eLife.05397.016)

Since fibril--virion complexes are already present before ejaculation or form rapidly post emission ([@bib81]), we next investigated whether CLR01 could displace virions from preformed fibril--virion complexes. Remarkably, CLR01 but not CLR03 substantially reduced the number of virions covering the surface of SEVI, PAP85-120, and SEM1(49-107) fibrils ([Figure 4C](#fig4){ref-type="fig"}). We excluded the possibility that CLR01 quenches the fluorescence of YFP-tagged virions by analyzing virions treated with CLR01 or controls by confocal microscopy. We found that treatment of virions with CLR01 did not affect virion fluorescence ([Figure 4D](#fig4){ref-type="fig"}) or the number of fluorescent particles ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). However, CLR01-treated virions were dispersed throughout the chamber indicating that their biophysical properties might be altered ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Our results demonstrate that CLR01 not only prevents the interaction of fibrils with virions but also displaces viral particles from preformed fibril--virion complexes.

The combined effects of CLR01 on fibril architecture ([Figures 2, 3](#fig2 fig3){ref-type="fig"}) and the formation of fibril--virion complexes ([Figure 4A--C](#fig4){ref-type="fig"}) led us to investigate whether the tweezer might diminish the infection-enhancing property of seminal amyloids. First, we analyzed possible cytotoxic effects of the tweezer in TZM-bl cells, a HIV reporter cell line commonly used to study virus infection ([@bib49]; [@bib81]). We found that CLR01 and CLR03 did not cause cytotoxic effects at concentrations up to 500 µM, whereas the surfactants Triton X-100, nonoxynol 9 and sodium dodecyl sulfate (SDS) were highly toxic ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Thus, CLR01 does not act in a manner similar to non-ionic or anionic surfactants.

Next, preformed fibrils were treated for 5 min with CLR01, CLR03, or buffer. After addition of a low dose of CCR5-tropic HIV, the resulting mixture was added to TZM-bl cells and infection was measured via β-galactosidase activity 3 days later. As previously reported ([@bib49]; [@bib67]; [@bib3]), the three semen-derived amyloids augmented HIV infection in a dose-dependent manner with maximal enhancements between 33- to 64-fold ([Figure 4E](#fig4){ref-type="fig"}). Remarkably, pretreatment of SEVI, PAP85-120, and SEM1(49-107) amyloid with CLR01 eliminated the infection-enhancing property of the fibrils, while CLR03 had no effect ([Figure 4E](#fig4){ref-type="fig"}). Thus, CLR01 abrogates the infection enhancing activity of seminal amyloids.

CLR01 exhibits direct anti-HIV activity {#s2-5}
---------------------------------------

In addition to engaging amyloid fibrils ([Figures 3, 4A](#fig3 fig4){ref-type="fig"}), CLR01 also appeared to have a direct effect on viral particles ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). To study the consequences of this interaction in more detail, a CXCR4- and CCR5-tropic HIV-1 NL4-3 recombinant ([@bib61]) and two CCR5-tropic transmitted/founder viruses ([@bib57]) were pretreated with CLR01 or controls and then examined for infectivity. Remarkably, CLR01 but not CLR03 abrogated viral infectivity in a dose-dependent manner with IC~50~ values ranging from ∼13.7 to 20.1 µM ([Figure 5A](#fig5){ref-type="fig"}). This reduction in infectivity was only observed when virions were exposed to CLR01 and not when target cells were pretreated with the tweezer ([Figure 5B](#fig5){ref-type="fig"}). Thus, in addition to its anti-amyloid properties, CLR01 also has direct anti-HIV activity that is independent of the viral co-receptor tropism or strain.10.7554/eLife.05397.017Figure 5.CLR01 has direct anti-HIV-1 activity.(**A**) CLR01 blocks HIV-1 infection by targeting virions. The CXCR4 (X4)-tropic lab-adapted HIV-1 NL4-3 strain, a CCR5 (R5)-tropic V3 loop recombinant thereof, and two R5-tropic transmitted/founder viruses (THRO and CH058) were incubated with CLR01 or CLR03 for 10 min and then used to infect TZM-bl cells. Infection rates were determined 3 days post infection. Values represent mean β-galactosidase activities derived from triplicate infections ±SD (RLU/s: relative light units per second). (**B**) The antiviral activity of CLR01 is not directed against the cell. TZM-bl cells were exposed to CLR01 or CLR03 for 1 hr. Thereafter, cell culture medium was removed and cells were infected with the indicated viruses. Infection rates were determined 3 day post infection. Values represent mean β-galactosidase activities derived from triplicate infections ±SD (RLU/s: relative light units per second).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.017](10.7554/eLife.05397.017)10.7554/eLife.05397.018Figure 5---figure supplement 1.Poly-L-lysine counteracts the antiviral activity of CLR01.CLR01 (40 µM) was titrated with poly-L-lysine. After a 10 min incubation with HIV-1 these mixtures were used to infect TZM-bl cells. Infection rates were determined 3 days post infection via a β-galactosidase assay. Values represent normalized mean infection rates ±SEM. Unpaired t-tests were used to compare the buffer control to the CLR01 condition at each poly-L-lysine concentration (ns denotes not significant; \* denotes p \< 0.05; \*\* denotes p \< 0.01).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.018](10.7554/eLife.05397.018)10.7554/eLife.05397.019Figure 5---figure supplement 2.Coated BSA does not antagonize the antiviral activity of CLR01.Microtiter plates were coated over night with the indicated amounts of BSA. After a 20-min incubation at room temperature, serial dilutions of CLR01 were added and incubated with HIV-1 for another 10 min at room temperature. With these mixtures, TZM-bl cells were infected. Infection rates were determined 3 days post infection. (**A**) Values represent mean β-galactosidase activities derived from triplicate infections ±SD (RLU/s: relative light units per second). (**B**) Values represent normalized mean infection rates derived from triplicate infections ±SD.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.019](10.7554/eLife.05397.019)10.7554/eLife.05397.020Figure 5---figure supplement 3.BSA does not antagonize the antiviral activity of CLR01.CLR01 (220 µM) was titrated with the indicated concentrations of BSA. HIV-1 was incubated with these mixtures for 10 min and then used to infect TZM-bl cells. Infection rates were determined 3 days post infection via a β-galactosidase assay. Values represent normalized mean infection rates derived from triplicate measurements ±SD. Unpaired t-tests were used to compare the buffer control to the CLR01 condition at each BSA concentration (\*\* denotes p \< 0.01; \*\*\* denotes p \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.020](10.7554/eLife.05397.020)10.7554/eLife.05397.021Figure 5---figure supplement 4.Preclearing CLR01 via centrifugation does not affect antiviral activity.CLR01 (50 µM) was centrifuged at 20,000×*g* and 20°C for 20 min. HIV-1 92TH014 was incubated for 10 min with the supernatant (S) or the pellet fraction (P). As a control, virus was also incubated either with PBS (Buffer) or 50 µM CLR01 that was not centrifuged (NC). After infection of TZM-bl cells with these mixtures infection rates were measured 2 days post infection. Values represent mean β-galactosidase activities derived from triplicate infections ±SD (RLU/s: relative light units per second). Unpaired t-tests were used to compare the buffer control to each CLR01 condition at each poly-L-lysine concentration (ns denotes not significant; \*\* denotes p *\<* 0.01; \*\*\* denotes p \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.021](10.7554/eLife.05397.021)

Exposure of CLR01 to poly-L-lysine prior to incubation with virions abrogated its anti-HIV-1 activity in a dose-dependent manner ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Near-complete inhibition was achieved with 75 nM poly-L-lysine. Thus, the lysine-binding cavity of CLR01 plays an important role in the antiviral ([Figure 5](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) and anti-amyloid ([Figure 2](#fig2){ref-type="fig"}; [Figure 2---figure supplements 3, 5](#fig2s3 fig2s5){ref-type="fig"}; [Figure 3](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) activities of CLR01.

Incubation of the tweezer in solutions containing up to 5% (sevenfold molar excess) coated or free BSA did not reduce the anti-HIV activity of CLR01 ([Figure 5---figure supplements 2, 3](#fig5s2 fig5s3){ref-type="fig"}). Similarly, the antiviral activity of CLR01 was not reduced when CLR01 solutions were precleared of any aggregates via centrifugation ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). Moreover, the pellet fraction did not possess antiviral activity ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). These data strongly suggest that colloidal CLR01 aggregates do not contribute to the direct antiviral activity of CLR01.

Antiviral mechanism of CLR01 {#s2-6}
----------------------------

To define the underlying mechanism of this antiviral activity, we tested whether CLR01 disrupts the integrity of the viral membrane, leading to the release of the inner viral p24 capsid protein. HIV virions were exposed to buffer, CLR01 or CLR03 and then separated by centrifugation into a soluble fraction (containing free p24) and a sedimentable fraction (containing intact viral particles). ELISA measurements demonstrated that the amount of p24 was increased in the soluble fraction of CLR01-treated samples as compared to samples treated with CLR03 or buffer ([Figure 6A](#fig6){ref-type="fig"}). Time course experiments revealed that a 5-min incubation of virus with 10 µM CLR01 resulted in a 62% decrease in HIV infectivity, and a 10-min incubation achieved almost a 100% reduction ([Figure 6B](#fig6){ref-type="fig"}). Atomic force microscopy (AFM) of mouse leukemia virus particles (MLV) confirmed that treatment with CLR01 destroyed virion architecture ([Figure 6C,D](#fig6){ref-type="fig"}). This effect was independent of the presence of viral glycoproteins, since CLR01 also destroyed HIV-1 particles lacking gp120/41 (∆env) ([Figure 6C](#fig6){ref-type="fig"}), suggesting that CLR01 disrupts the integrity of the viral membrane.10.7554/eLife.05397.022Figure 6.CLR01 destroys retroviral particles and selectively disrupts raft-rich membranes.(**A**) CLR01 releases p24 capsid antigen from HIV particles. HIV-1 was incubated with PBS, 100 µM CLR03, or 100 µM CLR01 and centrifuged at 20,000×*g* and 4°C for 1 hr. The p24 content of the supernatant was determined via p24 ELISA. Values represent means ±SD. Unpaired t-tests were used to compare the buffer control to the CLR03 or CLR01 condition (ns denotes not significant; \*\* denotes p \< 0.01). (**B**) HIV-1 was incubated at 37°C with 10 µM CLR01 or buffer control. Aliquots were taken after different time points and analyzed regarding their infectivity using TZM-bl reporter cells. Values represent normalized mean infection rates derived from triplicate measurements ±SD compared to the buffer control (100%). Unpaired t-tests were used to compare the buffer control to the CLR01 condition at each time point (\*\*\* denotes p \< 0.001). (**C**) CLR01 destroys retroviral particles. Images obtained by atomic force microscopy (AFM) show single MLV and glycoprotein-deficient HIV particles before and after treatment with 100 µM CLR01. Scale bar: 100 nm. (**D**) CLR01 destroys MLV particles. Height distribution of MLV particles after treatment with buffer (left panel) or 100 µM CLR01 (right panel). Values were derived from AFM images shown in the insets. Scale bar: 2 µm. (**E**) CLR01 selectively destroys membranes with high lipid raft content. Giant unilamellar vesicles (GUVs) consisting of pure DOPC were labeled with *N*-Rh-DHPE (red). GUVs containing a mixture of DOPC, SM and Chol (45/25/30 mol%) were labeled with *N*-Rh-DHPE (red) and Bodipy-Chol (green). Both types of GUVs were filled with buffer containing the fluorophore ATTO 647 (blue) and treated with 150 µM CLR01 for the indicated times before images were taken by confocal microscopy. Note that ATTO 647 remains inside the DOPC GUVs treated with CLR01, but escapes the DOPC/SM/Chol GUVs treated with CLR01. Scale bar: 10 μm. (**F**) Upper panel: AFM images (10 µm scans) of a pure DOPC lipid membrane on mica before injection (0 min) and 1 min and 60 min after injection of 800 µl of 150 µM CLR01 in 10 mM NaH~2~PO~4~, pH 7.6 into the AFM fluid cell. The whole scan area is shown with a vertical color scale from dark brown to white corresponding to an overall height of 8 nm. The thickness of the hydrated membrane is 3.7 nm. Lower panel: AFM image (10 µm scan) of a DOPC/SM/Chol (45/25/30 mol%) lipid membrane on mica before injection (0 min) and 1 min and 60 min after injection of 800 µl of 150 µM CLR01 in 10 mM NaH~2~PO~4~, pH 7.6 into the AFM fluid cell. The whole scan area is shown with a vertical color scale from dark brown to white corresponding to an overall height of 8 nm and indicating a homogeneous lipid bilayer with coexisting domains in l~o~ (liquid-ordered) and l~d~ (liquid-disordered domain) phase. The height difference between domains is 1 nm; the l~d~ phase has a thickness of 4.0 nm.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.022](10.7554/eLife.05397.022)

The result that CLR01 destroys retroviral particles with IC~50~ values between ∼10 and 20 µM by compromising virion integrity was unexpected, particularly because the tweezer does not affect cell viability at these concentrations ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}) ([@bib75]; [@bib5]; [@bib25]). Viral membranes differ from cellular membranes in that they are two to threefold enriched in specific lipids, such as sphingomyelin and cholesterol, which can form microdomains termed lipid rafts ([@bib2]; [@bib8]; [@bib10]; [@bib38], [@bib39]; [@bib19]). We hypothesized that CLR01 might selectively disrupt lipid-raft enriched membranes. To test this hypothesis, dye-loaded giant unilamellar vesicles (GUV) were generated that consisted of either 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) to recapitulate a bilayer devoid of lipid rafts or a mixture of DOPC, sphingomyelin and cholesterol (DOPC/SM/Chol) to more closely resemble a lipid raft-rich viral membrane. Strikingly, CLR01 permeabilized the model viral membrane within 5--10 min while exhibiting no effect on the DOPC membrane, even after 60 min of incubation ([Figure 6E](#fig6){ref-type="fig"}). These results were confirmed by AFM at higher spatial resolution ([Figure 6F](#fig6){ref-type="fig"}). CLR01 treatment of a DOPC membrane that was deposited on mica surface did not affect bilayer stability, and the tweezer (white dots in [Figure 6F](#fig6){ref-type="fig"}) was homogenously distributed on the scan area. By contrast, the DOPC/SM/Chol raft mixture appeared as coexisting liquid-disordered (l~d~) and liquid-ordered (l~o~) domains, and CLR01 addition induced changes in phase coexistence and decreased height differences between both phases. After 60 min, distinct l~d~ and l~o~ domains were no longer visible, and CLR01 was homogenously distributed in the remaining fluid phase. Collectively, these data suggest that CLR01 selectively disrupts heterogeneous lipid-raft enriched membranes.

CLR01 does not form colloidal aggregates {#s2-7}
----------------------------------------

Inhibitors of amyloid formation may block fibril polymerization by forming colloidal aggregates that sequester peptide via non-specific interactions ([@bib14]). Likewise, small molecule aggregates might also interfere non-specifically with viral infection. However, neither inhibition of amyloidogenesis, amyloid remodeling nor inhibition of viral infection by CLR01 were affected by BSA, which would quench small-molecule aggregates ([@bib43]), or by clearance of any potential CLR01 aggregates by centrifugation ([@bib44]) ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5---figure supplements 2, 3, 4](#fig5s2 fig5s3 fig5s4){ref-type="fig"}).

To investigate whether CLR01 even forms colloidal aggregates, we performed various tests for CLR01 aggregation using the same buffers and CLR01 concentrations as employed in our biological experiments described above ([Figures 2A--C, 3A--C, 5A](#fig2 fig3 fig5){ref-type="fig"}). NMR dilution titrations provided experimental evidence for a very weak CLR01 dimer formation (K~a~ = ∼60 M^−1^) in PBS buffer (10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4), with ∼5% CLR01 dimers present when the CLR01 concentration was 500 µM ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This observation is consistent with previously published data ([@bib13]). Dimerization was totally absent in HEPES buffer (25 mM HEPES, 150 mM KOAc, 10 mM Mg(OAc)~2~, pH 7.4; [Figure 7B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Thus, CLR01 is predominantly monomeric.10.7554/eLife.05397.023Figure 7.CLR01 does not form colloid or micelle aggregates.(**A**) ^1^H NMR dilution titration of CLR01 from 6 mM to 100 μM in PBS leads to very weak dimerization; (**B**) in HEPES buffer CLR01 remains monomeric over the entire concentration range. (**C**) DOSY spectrum of 6 mM CLR01 in PBS buffer; cross peaks at 4.8 ppm correspond to aqueous solvent. (**D**) DOSY spectrum of 2 mM CLR01 in HEPES buffer; cross peaks between 2 and 4 ppm correspond to HEPES buffer, cross peaks at 4.8 ppm correspond to the aqueous solvent. (**E**) Attempted cmc determination by analysis of the I~392~/I~373~ emission intensity ratio of 10 μM PBS-buffered pyrene solutions containing CLR01 from 30 nM to 500 μM produces a straight line, as opposed to the SDS control (data not shown). (**F**) DLS measurements of CLR01 (1 mM) in PBS or HEPES buffer show formation of minute amounts of particles with *R*~H~ ∼5--8 nm or ∼20--40 nm in PBS. No particles were detected in HEPES buffer. The vast majority of CLR01 molecules are too small to be detected and are presumably monomeric.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.023](10.7554/eLife.05397.023)10.7554/eLife.05397.024Figure 7---figure supplement 1.Aromatic proton shifts during dilution of PBS-buffered CLR01.Upfield shifts of the inner aromatic protons (2-H, 3-H, 13-H, 14-H) document their mutual inclusion inside the cavity of the other host molecule, leading to specific anisotropic shielding exclusively in the dimer. Thus, the NMR shift changes prove formation of weak dimers (*K*~*a*~ ∼60 M^−1^) and exclude unspecific aggregation, which would manifest as smaller chemical shift changes evenly distributed among the CH protons of CLR01.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.024](10.7554/eLife.05397.024)10.7554/eLife.05397.025Figure 7---figure supplement 2.Aromatic proton shifts during dilution of HEPES-buffered CLR01.Dilution titration of CLR01 in HEPES buffer did not produce any upfield shift of the aromatic protons; on the contrary, the monomer spectrum appeared at all concentrations, with sharp signals for all three protons.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.025](10.7554/eLife.05397.025)10.7554/eLife.05397.026Figure 7---figure supplement 3.Stejskal and Tanner Plot.Signal intensity in diffusion NMR experiments obeys the following law: ln(I/I0) = −γ^2^δ^2^G^2^(∆ − δ/3) D, where I = intensity at a given G, I~0~ = Intensity at G = 0, γ = Gyromagnetic ratio (for ^1^H: γ = 2.675 × 10^8^T^−1^s^−1^), δ = Length of diffusion gradient, ∆ = Diffusion shift, G = Gradient field intensity, and D = Diffusion coefficient. Signal intensities are used to generate a Stejskal Tanner-Plot lg(I/I~0~) vs G^2^. Its slope yields the diffusion coefficient. Diffusion coefficient for CLR01 (6.4 mM in PBS): 2.433 × 10^−10^ m^2^s^−1^. By means of the Stokes Einstein equation one calculates the hydrodynamic radius: r(s) = (k\*T)/(6\*pi\*η\*D). The hydrodynamic radius for CLR01 (6.4 mM) was determined at 1.0075 × 10^−9^ m ∼10 Å in PBS buffer; for CLR01 (0.2 mM) the diffusion coefficient dropped to 2.702 × 10^−10^ m^2^s^−1^, corresponding to a hydrodynamic radius of 9.072 × 10^−9^ m ∼9 Å. In HEPES buffer, the diffusion coefficient for CLR01 (2.0 mM) was determined at 2.449 × 10^−10^ m^2^s^−1^, corresponding to hydrodynamic radius r(s) of 1.001 × 10^−9^ m ∼10 Å; for CLR01 (0.5 mM) the diffusion coefficient dropped to 2.579 × 10^−10^ m^2^s^−1^, corresponding to a hydrodynamic radius of 9.504 × 10^−9^ m ∼9 Å. In summary, almost identical r(s) values were found for PBS and HEPES buffer. Thus, at various concentrations even above those used in experiments, the tweezers only produced a hydrodynamic radius slightly above the monomeric species.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.026](10.7554/eLife.05397.026)

Diffusion NMR (DOSY) experiments in both buffers revealed CLR01 hydrodynamic radii of ∼0.9--1.0 nm, slightly above the monomeric species ([Figure 7C,D](#fig7){ref-type="fig"}, [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). Microcalorimetric dilution titrations revealed only minute endothermic heat changes, which argue strongly against an extensive aggregation process (data not shown). Pyrene fluorescence revealed that no critical micelle concentration (cmc) could be determined in a wide concentration range (0--0.5 mM CLR01) encompassing fibril assembly and remodeling conditions ([Figure 7E](#fig7){ref-type="fig"}). Dynamic light scattering (DLS) experiments showed CLR01 particles with hydrodynamic radius *R*~H~ = 5--8 nm in PBS at concentration between 200 and 1000 μM, plus a very minor fraction of particles with a *R*~H~ = 20--40 nm ([Figure 7F](#fig7){ref-type="fig"}; data not shown). We did not observe CLR01 particles with a *R*~H~ of ∼95--400 nm, which is the size range typically associated with colloidal small-molecule aggregates ([@bib43]). No CLR01 particles could be detected at 10 or 50 μM in PBS (data not shown). In HEPES buffer, no particles were detected at any of the concentration tested (between 10 and 1000 μM) ([Figure 7F](#fig7){ref-type="fig"}; data not shown). The ∼0.9--1 nm hydrodynamic radius of CLR01 revealed by DOSY ([Figure 7C,D](#fig7){ref-type="fig"}) is below the detection limit of our DLS instrument, and hence, we cannot resolve the CLR01 monomer ([Figure 7F](#fig7){ref-type="fig"}). Importantly, DLS overemphasizes large particles because the scattered-light intensity is proportional to the square of the particle mass. The scattering intensity in the solutions of CLR01 (1 mM) in PBS was ∼3% that of similar samples containing Mg~3~(PO~4~) colloids (10 mM Mg~3~(PO~4~)) or SDS micelles (2% SDS (wt/vol)), suggesting that the observed species represented a small fraction of the CLR01 molecules (data not shown). Thus, under all assay concentrations the vast majority of the tweezer molecules are monomeric. Minute amounts of dimers or higher order species may be present at high concentrations of CLR01 in some cases in PBS (fibril assembly buffer) but are absent from the HEPES buffer (fibril remodeling buffer). Thus, it is highly unlikely that colloidal CLR01 aggregates contribute to the observed activity of the tweezer.

CLR01 exhibits broad antiviral activity against enveloped viruses {#s2-8}
-----------------------------------------------------------------

CLR01 exhibited a surprising ability to disrupt viral membranes ([Figures 5A, 6A,C--F](#fig5 fig6){ref-type="fig"}), but did not affect cell viability like various non-ionic and anionic surfactants ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). We therefore explored whether CLR01 could act as a general inhibitor of enveloped viruses. To test this concept, human cytomegalovirus (HCMV), herpes simplex virus type 2 (HSV-2), and hepatitis C virus (HCV) were treated with CLR01 or CLR03 and then assessed for their ability to infect target cells. Remarkably, CLR01, but not CLR03, reduced infection rates of all three analyzed enveloped viruses ([Figure 8A--C](#fig8){ref-type="fig"}). By contrast, CLR01 did not inhibit infection by the non-enveloped human adenovirus type 5 (HAdV5) ([Figure 8D](#fig8){ref-type="fig"}). Thus, the tweezer is a broad-spectrum inhibitor of enveloped viruses, including viruses that can be sexually transmitted such as HIV-1, HSV-2, and HCV.10.7554/eLife.05397.027Figure 8.CLR01 is a broad-spectrum inhibitor of enveloped viruses.(**A**) Human cytomegalovirus was incubated with PBS, 100 µM CLR03, or 100 µM CLR01. Afterwards, HFF cells were infected and immediate early (IE) antigen positive cells were counted 1 day post infection as a measure for infectivity. Values are means ±SD (n = 3). Unpaired t-tests were used to compare the buffer control to the CLR03 or CLR01 condition (ns denotes not significant; \*\*\* denotes p \< 0.001). (**B**) Herpes simplex virus type 2 comprising a GFP reporter gene was treated with PBS, 100 µM CLR03 or 100 µM CLR01 and added to Vero cells. GFP-positive cells were counted using flow cytometry 2 days post infection. Values represent means ±SD (n = 3). Unpaired t-tests were used to compare the buffer control to the CLR03 or CLR01 condition (ns denotes not significant; \*\*\* denotes p \< 0.001). (**C**) A luciferase encoding hepatitis C virus was treated with 150 µM CLR01 or 150 µM CLR03 and used for infection of Huh-7.5 reporter cells. Infection was measured 3 days post infection. Values represent means ±SEM (n = 3). Unpaired t-tests were used to compare the buffer control to the CLR03 or CLR01 condition (ns denotes not significant; \*\*\* denotes p \< 0.001). (**D**) A GFP-reporter adenovirus type 5 was added to A549 cells after treatment with 158 µM CLR01 or 158 µM CLR03. GFP positive cells were counted using flow cytometry 1 day post infection. Values represent means ±SD (n = 3). Unpaired t-tests were used to compare the buffer control to the CLR03 or CLR01 condition (ns denotes not significant).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.027](10.7554/eLife.05397.027)

CLR01 antagonizes the infection-enhancing property of human semen {#s2-9}
-----------------------------------------------------------------

CLR01 binds exposed lysine and arginine residues in amyloidogenic peptides ([@bib75]; [@bib5]; [@bib64]; [@bib74]; [@bib1]; [@bib15]; [@bib95]). In vivo, the amyloids we examined are present in the complex environment of human semen. We wondered whether the interactions between CLR01 and seminal peptides might be hindered in conditions resembling those in seminal fluid. To test whether this is the case, lyophilized PAP248-286 was dissolved in an artificial semen simulant (AS) ([@bib60]; [@bib59]) containing 50 mg/ml BSA and agitated until fibril formation was complete. These PAP248-286(AS) fibrils were then diluted in AS and incubated with CLR01. A reduction in ThT fluorescence intensity to 43% of the initial value was detected ([Figure 9A](#fig9){ref-type="fig"}). This finding confirms that CLR01 maintains its amyloid-remodeling activity in a complex solution resembling seminal fluid.10.7554/eLife.05397.028Figure 9.CLR01 diminishes the infection enhancing property of semen.(**A**) SEVI fibrils were formed in an artificial semen simulant (AS) ([@bib60]). The resulting fibrils were then diluted to 20 µM in AS and treated with 200 µM CLR01 or CLR03, or with buffer for 2 hr. Fibril integrity was assessed using ThT fluorescence. Values represent means ±SEM (n = 4). A one-way ANOVA with the post hoc Dunnett\'s multiple comparisons test was used to compare the buffer alone control to the other conditions (ns denotes not significant; \*\* denotes p \< 0.01). (**B**) CLR01 abrogates semen-mediated enhancement of HIV infection. Seminal plasma (10%) or cell culture medium containing CLR01 or CLR03 was mixed with CCR5-tropic HIV-1 or transmitter/founder HIV-1 CH058. After 10 min, TZM-bl cells were infected and infectivity was measured 3 day post infection. Shown are the n-fold increased infection rates obtained for semen-treated virus relative to those of medium-treated virus. Values represent means ±SD (n = 4). Unpaired t-tests were used to compare the buffer control (0 µM compound) to the CLR03 or CLR01 condition at each concentration (ns denotes not significant; \* denotes p \< 0.05; \*\* denotes p \< 0.01; \*\*\* denotes p \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.05397.028](10.7554/eLife.05397.028)

Finally, we tested whether the molecular tweezer inhibited semen-mediated infection enhancement, as described ([@bib48]). Seminal plasma, which was obtained from pooled semen of 10 donors, was treated with CLR01 or CLR03. Thereafter, a CCR5-tropic lab-adapted virus or a transmitted/founder virus were incubated with 10% of these solutions followed by infection of TZM-bl cells. Consistent with previous studies ([@bib49]; [@bib24]; [@bib69]; [@bib28]), seminal plasma enhanced infection of both viruses by 10- or 8-fold, respectively ([Figure 9B](#fig9){ref-type="fig"}). CLR01 decreased viral infectivity enhancement in a concentration-dependent manner, while CLR03 had no effect on semen-mediated infection enhancement ([Figure 9B](#fig9){ref-type="fig"}). At a CLR01 concentration of 31 µM, any stimulatory effect of semen was abolished ([Figure 9B](#fig9){ref-type="fig"}). Thus, CLR01 prevents HIV infection in the presence of semen, the main vector for viral transmission in the human population.

Discussion {#s3}
==========

Despite the development of several different classes of topical microbicides, none have proven safe and effective at HIV prevention. The failure of topical microbicide candidates in previous clinical trials has been attributed to lack of adherence ([@bib82]; [@bib42]), adverse effects ([@bib45]), and a greatly diminished antiviral efficacy in the presence of semen ([@bib56]; [@bib96]). This bodily fluid is not only the main vector for HIV transmission but also contains cationic amyloid fibrils that markedly increase viral infectivity ([@bib9]; [@bib51]). Various biological polyanions such as heparin or other glycosaminoglycans can prevent these cationic fibrils from enhancing HIV infection ([@bib69]). Unfortunately, however, such anionic polymers have been unsuccessful in past clinical microbicide trials due to their poor bioavailability and induction of inflammatory responses in the genital tract, which actually augment HIV transmission by recruiting HIV-susceptible target cells to the genital mucosa ([@bib40]; [@bib83]). We have suggested that future microbicide endeavors should focus on agents that simultaneously and safely target HIV and the host factors that are exploited by the virus to facilitate its transmission ([@bib9]; [@bib96]; [@bib68]). Here, we report that CLR01, a lysine- and arginine-specific molecular tweezer ([@bib16]), not only counteracts the infection-enhancing activity of seminal amyloids and semen, but also directly destroys HIV virions ([Figure 10](#fig10){ref-type="fig"}). CLR01 is a highly promising topical microbicide candidate because it possesses potent antiviral and anti-amyloid activity, displays minimal toxicity in vivo ([@bib64]; [@bib4]; [@bib15]), and is efficacious in human seminal fluid.10.7554/eLife.05397.029Figure 10.CLR01 acts as a dual-function inhibitor of viral infection.Schematic overview of the anti-amyloid and antiviral effects of CLR01.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.029](10.7554/eLife.05397.029)

It was surprising that CLR01 not only affected the formation and function of seminal amyloids but also displayed a broad and direct antiviral activity against HIV and other enveloped viruses ([Figure 8](#fig8){ref-type="fig"}). These diverse activities made us concerned that CLR01 might disrupt amyloidogenesis and viral infection via a non-specific mechanism involving the formation of colloidal CLR01 aggregates ([@bib43], [@bib44]; [@bib72]; [@bib14]). Nevertheless, multiple lines of evidence argue against a non-specific, colloidal mechanism of CLR01 activity. First, using a variety of biophysical techniques, we were unable to detect significant quantities of colloidal CLR01 aggregates under the conditions employed in our experiments ([Figure 7](#fig7){ref-type="fig"}). Second, the anti-amyloid and antiviral activity of CLR01 was unaffected by high concentrations of BSA ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5---figure supplement 2 and 3](#fig5s2 fig5s3){ref-type="fig"}; [Figure 9A](#fig9){ref-type="fig"}), which would adsorb and quench the activity of any potential colloidal micelles ([@bib43]; [@bib14]). Third, attempts to preclear CLR01 solutions by centrifugation to remove any colloidal aggregates ([@bib44]; [@bib14]) had no effect on CLR01 anti-amyloid or antiviral activity ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). Fourth, the shallow CLR01 dose--response curves are not typical of colloidal aggregate inhibitors, which typically exhibit steep dose--response curves ([@bib72]). Finally, a feature of small molecules that form colloidal aggregates is that they are non-specific inhibitors ([@bib43], [@bib44]; [@bib14]). By contrast, CLR01 displays specificity for amyloidogenesis by peptides that harbor lysine and arginine residues. Thus, if the lysine and arginine residues of PAP248-286 or PAP85-120 are replaced with alanine, then CLR01 can neither inhibit fibril assembly nor remodel preformed fibrils ([Figures 2G--I, 3I--L](#fig2 fig3){ref-type="fig"}). Likewise, the antiviral activity of CLR01 is restricted to enveloped viruses and CLR01 is ineffective against non-enveloped viruses ([Figure 8](#fig8){ref-type="fig"}). This specificity is inconsistent with an indiscriminate, non-specific mechanism of action mediated by colloidal CLR01 aggregates. Importantly, the anti-amyloid and antiviral activity of CLR01 could be eliminated by excess lysine or poly-L-lysine. Thus, the lysine-binding cavity of CLR01 plays an important role in both anti-amyloid and antiviral activity.

The ability of CLR01 to antagonize seminal amyloid in the presence of BSA and to prevent HIV infection in the presence of seminal fluid ([Figure 9](#fig9){ref-type="fig"}) raises another question. Why is CLR01 activity not quenched by lysine or arginine residues on the surface of BSA or on other proteins abundant in seminal fluid? Here, it is important to consider the profound difference between freely accessible lysines on intrinsically unstructured domains, which can all be complexed by the tweezers, and lysines in folded proteins whose surface often prohibits the sterically demanding tweezer molecule to approach a lysine residue close enough for the threading mechanism ([Figure 1B](#fig1){ref-type="fig"}). The interaction between free lysine and CLR01 has a *K*~*d*~ of ∼10 µM, with fast on and off rates ([@bib16]; [@bib6]; [@bib13]). On folded proteins, however, only a few lysines are accessible for the relatively large molecular skeleton of the tweezers. For example, only 5 of 17 surface lysines in a 14-3-3 protein are most likely to be complexed by CLR01 ([@bib6]). Even in an unstructured small protein, such as Aβ, CLR01 has clear preference for the free Lys16 over Lys28 ([@bib75]) because the latter is engaged in stabilizing hydrophobic interactions and salt bridges ([@bib63]; [@bib34]; [@bib91]). Moreover, because of the high on and off rates, CLR01 is expected to only disrupt relatively weak interactions as well as events that depend on critical and accessible lysine or arginine residues. Therefore, the tweezer has shown selectivity in multiple cases that on first impression may appear counter-intuitive. For example, inhibition of abnormal protein aggregation is typically achieved at ∼1:1--1:5 protein:CLR01 concentration ([@bib75], [@bib74]; [@bib1]), whereas disruption of controlled protein polymerization, for example, of tubulin, requires ∼55-fold excess CLR01 ([@bib4]) and enzyme inhibition requires ∼1000-fold excess CLR01 ([@bib78]). Moreover, in vivo, CLR01 shows no toxicity at doses 2--3 orders of magnitude above those needed to enable clearance of amyloid ([@bib5]; [@bib64]; [@bib4]; [@bib15]). Thus, selectivity for lysine-bearing amyloid conformers in complex biological fluids is achieved by CLR01.

We suggest that the lysine-rich nature of seminal amyloid peptides ([Figure 1C--E](#fig1){ref-type="fig"}) makes them unusually sensitive to CLR01 activity. Indeed, substoichiometric CLR01 concentrations (relative to peptide monomers) suffice to inhibit PAP248-286, PAP85-120, and SEM1(45-107) fibrillization ([Figure 2D--F](#fig2){ref-type="fig"}). Remarkably, substoichiometric CLR01 concentrations (relative to peptide monomers) also sufficed to effectively remodel SEVI and PAP85-120 fibrils ([Figure 3G,H](#fig3){ref-type="fig"}). Curiously, SEM1(45-107) fibrils could not be remodeled by CLR01. Why SEM1(45-107) fibrils were refractory to CLR01 remains unclear and requires further study. CLR01 may require longer time periods to remodel SEM1(45-107) fibrils as with remodeling of Aβ fibrils, which required several weeks ([@bib75]). It will also be important to determine whether some lysine and arginine residues in PAP248-286, PAP85-120, and SEM1(45-107) are more critical than others for CLR01 activity.

How does CLR01 directly antagonize viral infection? Since the CLR03 control, which has a similar negative charge as CLR01 ([@bib75]), was entirely ineffective at blocking viral infection, a purely polyanion-like mechanism that prevents the interaction of virions and cells by increasing charge repulsions ([@bib55]; [@bib86]) could be excluded. Instead, we demonstrate that CLR01 selectively disrupts membranes containing elevated levels of sphingomyelin and cholesterol ([Figure 6](#fig6){ref-type="fig"}). Envelopes of HIV-1, herpes viruses, and HCV differ significantly from the cellular plasma membrane as they are more highly enriched in these and other lipids ([@bib84]; [@bib8]; [@bib10]; [@bib38], [@bib39]; [@bib46]). Indeed, the HIV membrane possesses a highly unusual lipid composition, which is distinct even from the detergent-resistant microdomains typically found in the plasma membrane, indicating that HIV budding involves a specific lipid raft clustering process ([@bib8]). For example, although HIV membrane resembles lipid raft microdomains in that it is enriched for saturated lipids, phosphatidylserine, plasmalogen-phosphatidylethanolamine, cholesterol, and sphingolipids, it is also enriched for the unusual sphingolipid dihydrosphingomyelin ([@bib8]; [@bib38], [@bib39]). The unique lipid composition of viral membranes may render them uniquely sensitive to CLR01.

Importantly, unlike various non-ionic and anionic surfactants, CLR01 has minimal effects on cell viability ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Thus, CLR01 might leverage a therapeutic opportunity provided by the physiological difference between static viral membranes and biogenic cellular membranes capable of self-repair. Static viral membranes are unable to withstand disruption by CLR01, whereas cells can likely repair lipid-raft-rich regions of the plasma membrane that might be disrupted by CLR01. In this regard, CLR01 may possess similarities to other broad-spectrum antivirals such as LJ001, a lipophilic aryl methyldiene rhodanine derivative, which selectively disrupt diverse viral membranes but are ineffective against non-enveloped viruses, and also do not disrupt cell membranes ([@bib89]; [@bib90]; [@bib85]). We investigated whether the tweezer might recognize the charged lipid head groups but found via NMR chemical-shift experiments that this was not the case (data not shown). However, experiments on various phase boundaries strongly indicated that the tweezer could migrate into lipid bilayers due to its amphiphilic character (data not shown). A pronounced destabilizing effect may be triggered if this happens at the edge of lipid rafts that are enriched in virion membranes. Importantly, HSV-2, HCMV, and HCV can also be transmitted via sexual intercourse ([@bib23]; [@bib65]; [@bib79]). Thus, a CLR01-based microbicide may not only protect from HIV-1 acquisition but also from other major human pathogens.

CLR01 binding to lysine residues could potentially disrupt normal protein function leading to toxicity or side effects. However, CLR01 showed no signs of cytotoxicity in this study and has previously been safely employed in multiple cell and animal models ([@bib75]; [@bib5]; [@bib64]; [@bib4]). For example, transgenic mice that were given 10 mg CLR01 a day per 1 kg body weight intraperitoneally for 30 days showed no apparent toxicity or adverse effects ([@bib4]). Moreover, it is conceivable that the application of CLR01 on mucosal surfaces should be even safer compared to its systemic administration.

Unlike previous microbicide candidates that block HIV infection by a single mechanism, a CLR01-based formulation would interfere with various essential steps in sexual HIV transmission ([Figure 10](#fig10){ref-type="fig"}). On a minute time frame, the tweezer destroys infectious HIV particles that are present in semen, prevents the formation of amyloid--virus complexes by neutralization of the fibril surface charge, and also displaces pre-bound virions from fibrils ([Figure 10](#fig10){ref-type="fig"}). On a longer time frame (hours), CLR01 not only prevents the formation of infection-enhancing seminal amyloids upon ejaculation but also remodels fibrils that are already abundant in semen after ejaculation or formed during semen liquefaction ([Figure 10](#fig10){ref-type="fig"}). Given the time frame of these effects, we suggest that the primary mechanism of CLR01 action is via its direct effect on the virus, and that the anti-amyloid effects, although potent, play a secondary role. Regardless, these combined antiviral and anti-amyloid activities and the encouraging safety data make CLR01 a promising broad-spectrum, topical microbicide against HIV-1 and other sexually transmitted viruses. We anticipate that large-scale synthesis of CLR01 could be relatively inexpensive (less than \$1 per mg), which would enable facile development as a broad-spectrum antiviral microbicide.

Materials and methods {#s4}
=====================

Computational details {#s4-1}
---------------------

The interactions of PAP248-286 with the molecular tweezer CLR01 and the spacer CLR03 were investigated using Replica Exchange Molecular Dynamics (REMD) simulations ([@bib77]; [@bib58]) performed with Gromacs 4.6 ([@bib26]) and the CHARMM27 force field ([@bib41]; [@bib7]). The water solvent was treated explicitly using the TIP3P model ([@bib27]). The parameters for CLR01 and CLR03 were obtained using the Swissparam server and tested previously ([@bib97]; [@bib6]). The initial coordinates of PAP248-286 were taken from the Protein Data Bank, code 2L3H ([@bib52]). The temperature range for the REMD simulations was 290--330 K. The temperature distribution was obtained as described by [@bib62]. Here, we focused our discussion on the 300 K trajectory. Three systems were investigated: (1) PAP248-286, (2) PAP248-286 with 7 CLR01 molecules (one for each Lys or Arg residue, with the exception of Lys272 which was not sterically accessible in the initial structure but became available during the simulations), and (3) PAP248-286 with 8 CLR03 molecules interacting via the hydrogen phosphate groups with each Lys or Arg residue of PAP248-286. For each system, 22 replicas were simulated during 60 ns. The cluster analysis of the REMD simulations was performed with the gromos method using a cut-off value of 0.2 nm ([@bib12]).

Small molecules, peptides, and seminal plasma {#s4-2}
---------------------------------------------

All chemicals or biochemicals were from Sigma--Aldrich (St. Louis, MO) unless otherwise stated. CLR01 and CLR03 were generated as described previously ([@bib16]), and 7.4--20 mM stock solutions were prepared in water or in PBS. Synthetic peptides PAP248-286, PAP248-286(Ala), PAP85-120, and SEM1(45-107) or (49-107) were purchased from Keck Biotechnology Resource Laboratory (Yale University, New Haven, CT) or Celtek peptides (Franklin, TN). PAP85-120(Ala) was purchased from Bachem (King of Prussia, PA). For fibril formation, peptides were reconstituted and assembled into fibrils as previously described ([@bib49]; [@bib67]; [@bib3]). L-lysine, poly-L-lysine hydrobromide (molecular weight 4000--15,000 by viscosity), and poly-L-lysine hydrobromide (molecular weight 70,000--150,000 by viscosity) were from Sigma--Aldrich. Seminal plasma represents the cell-free supernatant fraction of pooled human semen centrifuged at 20,000×*g* for 30 min at 4°C.

^1^H NMR dilution titration {#s4-3}
---------------------------

CLR01 was dissolved in PBS (10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4) or HEPES buffer (25 mM HEPES, 150 mM KOAc, 10 mM Mg(OAc)~2~, pH 7.4) and diluted from 6.4 mM to 100 μM. In the corresponding ^1^H NMR spectra, the chemical shift changes of the inner aromatic proton forming a binding isotherm, were analyzed by nonlinear regression and furnished the 1:1 dimerization constant.

DOSY experiments {#s4-4}
----------------

CLR01 was dissolved in PBS or HEPES buffer (pH 7.4) and diluted from 6.4 mM to 200 μM. DOSY spectra were measured for all concentrations of CLR01, and the diffusion coefficient was determined from the corresponding Stejskal and Tanner Plot. The diffusion coefficient was converted into the hydrodynamic radius by way of the Stokes--Einstein equation.

Isothermal titration calorimetry (ITC) experiments {#s4-5}
--------------------------------------------------

A dilution experiment was performed with a HEPES buffered solution of CLR01 (6 mM--100 μM). Evolved heats were very small (0.1--0.2 μcal per injection) and endothermic.

Critical micelle concentration (cmc) determination {#s4-6}
--------------------------------------------------

Pyrene (10 μM) was dissolved in PBS or HEPES buffer containing 5% of DMSO, and the intensity ratio of both fluorescence emission maxima I~392~/I~373~ was determined at various CLR01 concentrations (10--500 μM). As a reference, SDS solutions in the same buffer were analyzed at 0.1--50 mM (cmc at 6--8 mM).

Dynamic light scattering (DLS) experiments {#s4-7}
------------------------------------------

CLR01 was dissolved in phosphate-buffered saline (PBS 10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4) or 25 mM HEPES, 150 mM KOAc, 10 mM Mg(OAc)~2~, pH 7.4 at 10, 50, 200, 500, or 1000 μM. The solutions were transferred to DLS cuvettes and centrifuged for 30 min at 5000×*g* to pellet dust particles. Solutions were measured using an in-house-built system with a He-Ne laser, model 127 (wavelength 633 nm, power 60 mW; Spectra Physics Lasers, Mountain View, CA). Light scattered at 90° was collected using image-transfer optics and detected by an avalanche photodiode built into a 256-channel PD2000DLS correlator (Precision Detectors, Bellingham, MA). The size distribution of scattering particles was reconstructed from the scattered light correlation function using PrecisionDeconvolve software (Precision Detectors) based on the regularization method by Tikhonov and Arsenin ([@bib80]). As a reference, Mg~3~(PO~4~) colloids (10 mM Mg~3~(PO~4~)) or SDS micelles (2% SDS (wt/vol)) were analyzed.

Fibril assembly and remodeling assays {#s4-8}
-------------------------------------

For assembly experiments, each reconstituted peptide was incubated with CLR01 or CLR03 and agitated at 37°C at 1400 rpm. At various time points, aliquots (1 µl) were removed and added to 25 µM ThT in PBS (200 µl). Changes in fluorescence (excitation: 440 nm, emission: 482 nm) were measured using a Tecan Safire2 microplate reader (Tecan, Männedorf, Switzerland). To assess the extent of fibril assembly using sedimentation analysis, fibril samples (20 µM fibrils, 100 µl volume) were centrifuged for 10 min at 13,200 rpm. The supernatant was carefully removed and transferred to a new tube, and the pellet was redissolved in an equal volume (100 µl) of buffer. Then, 50 µl of 3× sample buffer (6% SDS, 187.5 mM Tris, 30% glycerol, 10% β-mercaptoethanol, 0.05% bromophenol blue, pH 6.8) was added to the supernatant and pellet fractions. Samples were analyzed by SDS-PAGE using 10--20% Tris-Tricine peptide gels and XT Tricine running buffer (Bio-Rad, Hercules, CA) and visualized by coomassie staining. A gradient of soluble peptide controls were also run on the gels. Densitometry (using Image J software) was used to quantify the percent of protein in the pellet fractions by comparing to a standard curve created from the soluble peptide controls. For amyloid-remodeling experiments, fibrils (20 µM, based on peptide monomer concentrations) were diluted into an assay buffer (25 mM HEPES, 150 mM KOAc, 10 mM Mg(OAc)~2~, pH 7.4) in the presence of ATP (5 mM) and incubated with either CLR01 or CLR03. Aliquots (5 µl) were removed at various time points and added to 25 µM ThT in PBS (55 µl). ThT fluorescence was measured as above. The artificial semen simulant was prepared as described previously ([@bib60]; [@bib59]), and is comprised of: 18 mM citrate; 40 mM chloride; 7 mM calcium; 4.5 mM magnesium; 28 mM potassium; 220 mM sodium; 2 mM zinc; 15 mM fructose; 6 mM glucose; 50.4 mg/ml BSA; 7 mM lactic acid; 7.5 mM urea; all in a 123 mM sodium phosphate base, pH 7.7. In some fibril assembly and remodeling experiments, BSA (10 mg/ml) was also included. To assess any contribution of potential colloidal CLR01 aggregates, CLR01 was first reconstituted at the requisite concentration for fibril assembly or remodeling reactions, and then centrifuged at 16,100×*g* for 20 min at 25°C. The supernatant fraction was then collected and used in fibril assembly or remodeling reactions. For some fibril assembly and remodeling reactions, CLR01 was incubated with a 200-fold molar excess of L-lysine or 10-fold molar excess of poly-L-lysine (molecular weight 4000--15,000 by viscosity) for 10 min on ice prior to addition to unassembled peptide or preformed fibrils. To determine IC~50~ or EC~50~ values and Hill slopes for dose--response relationships, the data were analyzed using GraphPad Prism software. A nonlinear regression analysis (log(inhibitor) vs response--variable slope) was used and fitted with the least squares (ordinary) fit.

ThT displacement assay {#s4-9}
----------------------

Preformed SEVI, PAP85-120, or SEM1(45-107) fibrils (5 µM monomer) were preincubated with ThT (25 µM) for 30 min at room temperature. Buffer (PBS), CLR01 (250 µM), or a known competitor of ThT binding, BTA-1 (250 µM) ([@bib36]) were then added and incubated for 10 min at room temperature. ThT displacement was then assessed by fluorescence measurements.

Transmission electron microscopy {#s4-10}
--------------------------------

Aliquots were removed from the assembly and remodeling reactions, spotted for 10 min on Formvar carbon-coated grids (EM Sciences), stained for 5 min with 2% uranyl acetate, and washed with distilled water. Samples were visualized using a Jeol-1010 transmission electron microscope.

Circular dichroism spectroscopy {#s4-11}
-------------------------------

CD spectra were collected on an AVIV Model 410 Circular Dichroism Spectrometer. Mean residue ellipticity (MRE) was calculated using the equation MRE = θ/(10lcN) where θ is the measured ellipticity in millidegrees, l is the pathlength in cm, c is the molar protein concentration, and N is the number of residues.

Zeta potential {#s4-12}
--------------

PAP248-286, PAP85-120, and SEM1(49-107) fibrils were treated with a 10-fold excess of CLR01 or CLR03. After centrifugation at 20,000×*g* for 10 min, the pellets were resuspended in 1 mM KCl. Zeta potential was measured using the Zeta Nanosizer (Malvern Instruments, UK). To analyze the impact of lysine or poly-L-lysine on the binding of CLR01 to semen amyloids, SEVI fibrils were treated with a twofold excess of CLR01 and increasing concentrations of lysine (1, 10 and 100-fold excess over CLR01) or poly-L-lysine (molecular weight 70,000--150,000 by viscosity; 0.02, 0.25 and 2.5-fold excess of lysine monomer equivalents over CLR01). After centrifugation at 20,000×*g* for 10 min, samples were processed and measured as described above.

Confocal microscopy {#s4-13}
-------------------

Fibrils (200 µg/ml in PBS) were stained with Proteostat Amyloid Plaque Detection Kit (Enzo Life Sciences, Plymouth Meeting, PA). Fibrils were then treated with 20-fold excess CLR01 or CLR03 and mixed 1:2 with MLV-Gag-YFP virions. Samples were transferred to µ-slides VI0.4 (Ibidi, Munich, Germany) and imaged with a Zeiss LSM confocal microscope.

Effect of CLR01 on amyloid and semen-mediated enhancement of HIV infection {#s4-14}
--------------------------------------------------------------------------

The reporter cell line TZM-bl was obtained through the NIH ARRRP and cultured in cell culture medium (DMEM medium supplemented with 120 µg/ml penicillin, 120 µg/ml streptomycin, 350 µg/ml glutamine and 10% inactivated fetal calf serum (FCS), Gibco, Life Technologies, Frederick, MD). This cell line is stably transfected with an LTR-lacZ cassette and expresses CD4, CXCR4, and CCR5. Upon infection with HIV-1, the viral protein Tat is expressed which activates the long terminal repeat (LTR) resulting in the generation of β-galactosidase molecules.

Virus stocks of X4-tropic HIV-1 NL4-3, R5-tropic HIV-1 NL4-3 92TH014, and of the transmitter/founder viruses THRO.c and CH058.c (kindly provided by B Hahn) were generated by transient transfection of 293T cells as described ([@bib49]). After transfection and overnight incubation, the transfection mixture was replaced with 2 ml cell culture medium with 2% inactivated FCS. After 40 hr, the culture supernatant was collected and centrifuged for 3 min at 330×*g* to remove cell debris. Virus stocks were analyzed by p24 antigen ELISA and stored at −80°C.

To assess the effect of CLR01 and CLR03 on amyloid-mediated enhancement of HIV-1 infection, 10^4^ TZM-bl cells in 180 µl cell culture medium were seeded in 96-well flat-bottom plates the day before infection. 200 µg/ml fibrils (44 µM SEVI, 45 µM PAP85-120 fibrils, 30 µM SEM1(49-107) fibrils) were treated with a 20-fold molar excess of CLR01 or CLR03 for 10 min at room temperature, serially diluted fivefold and then mixed with R5-tropic HIV-1 NL4-3 92TH014 (0.5 ng/ml p24 antigen). After 5 min, 20 µl of these mixtures were added to TZM-bl cells and infection rates were determined 3 days post infection by detecting β-galactosidase activity in cellular lysates using the Tropix Gal-Screen kit (Applied Biosystems, Life Technologies, Frederick, MD) and the Orion microplate luminometer (Berthold, Bad Wildbad, Germany). All values represent reporter gene activities (relative light units per second; RLU/s) derived from triplicate infections minus background activities derived from uninfected cells.

To assess the effect of CLR01 and CLR03 on semen-mediated enhancement of HIV-1 infection, 10^4^ TZM-bl cells were seeded in 280 µl cell culture medium supplemented with 50 µg/ml gentamycin in 96-well flat-bottom plates the day before infection. Seminal plasma (20%) was treated with different concentrations of CLR01 or CLR03 (highest 925 µM) for 10 min at room temperature and then mixed with R5-tropic HIV-1 NL4-3 and CH058 (0.5 ng/ml p24 antigen). After 5 min, 20 µl of these mixtures were added to 280 µl TZM-bl cells. To minimize cytotoxic effects mediated by seminal plasma, the inoculums were replaced 2 hr later with fresh cell culture medium. Infection rates were determined as described above.

Cell viability {#s4-15}
--------------

The effect of CLR01, CLR03, nonoxynol-9, sodium dodecyl sulfate and Triton X-100 on the metabolic activity of TZM-bl cells was analyzed using the MTT assay. After 3 days of incubation, 20 µl of 5 mg/ml MTT (3-\[4,5-dimethyl-2-thiazolyl\]-2,5-diphenyl-2H-tetrazolium bromide) solution was added to the cells. After 4 hr the cell-free supernatant was discarded and formazan crystals were dissolved in 100 µl DMSO:Ethanol (1:2). Absorption was detected at 490 nm and corrected by the background absorption at 650 nm.

Antiviral activity of CLR01 on HIV-1, HCMV, HSV-2, HCV, and adenovirus infection {#s4-16}
--------------------------------------------------------------------------------

### HIV-1 {#s4-16-1}

In the virus treatment assay, R5- and X4-tropic HIV-1 NL4-3, and HIV-1 transmitter/founder viruses CH058 and THRO were titrated with CLR01 or CLR03 (0--150 µM). After incubation for 10 min at 37°C, 20 µl of these mixtures were added to 10^4^ TZM-bl cells seeded 1 day prior in 180 µl cell culture medium. For the cell-treatment assay, DMEM instead of virus was titrated with CLR01 or CLR03, incubated, and added to TZM-bl cells analogous to the virus treatment protocol. After a 2-hr incubation at 37°C, old medium was replaced by fresh cell culture medium, and cells were infected with the different HIV-1 strains. β-galactosidase activity was measured 3 days post infection. IC~50~ values were calculated with GraphPad Prism software.

### Human cytomegalovirus (HCMV) {#s4-16-2}

Human foreskin fibroblasts (HFFs) were maintained in minimal essential medium (MEM, Invitrogen, Germany) supplemented with 10% fetal calf serum (Invitrogen), 2 mM L-glutamine (Biochrom AG, Germany), 100 U of penicillin and 100 µg of streptomycin (Gibco/BRL) per ml, and 1 × non-essential amino acids (Biochrom AG). Production of HCMV stock virus was a derivative of strain TB40-BAC4 ([@bib76]), and all HCMV infection experiments were performed on HFF under serum-free conditions. To evaluate the inhibitory effect of compounds on virus entry, HCMV virus, corresponding to a multiplicity of infection of approximately 1 plaque forming unit, was pre-incubated with PBS, 100 µM CLR03, or 100 µM CLR01 for 30, 60, or 120 min, respectively, at 37°C in serum-free MEM. The virus/compound mixtures were then incubated for 16 hr with HFFs (1.7 × 10^4^/well) in a 96-well plate that was seeded 1 day prior to infection and washed twice with PBS before adding the mixtures. To determine infection rates, virus/compound mixtures were first removed by washing twice with PBS followed by fixation with ice-cold methanol for 10 min. HCMV-infected cells were visualized by indirect immunofluorescence staining for HCMV immediate-early (IE) antigen employing Mab13 (Argene) and cell nuclei staining by using 4′,6-diamidin-2-phenylindol (DAPI, Roche, Basel, Switzerland). HCMV infection rates for each compound were determined from images taken with the 10× objective lens and the fluorescence microscope Axio-Observer.Z1 (Zeiss, Germany) by counting numbers of IE-positive cells. Maximum inhibition of HCMV infection by CLR01 was found already after 30 min of incubation. The mean infection rate and standard deviation included the results from the different incubation times.

### Herpes simplex virus type 2 (HSV-2) {#s4-16-3}

HSV-2 comprising a GFP reporter gene was treated with PBS, 100 µM CLR03, or 100 µM CLR01 and added to Vero cells. GFP-positive cells were counted using flow cytometry 2 days post infection.

### Hepatitis C virus (HCV) {#s4-16-4}

HCV in vitro transcripts were generated and transfected using electroporation as described recently ([@bib32]). Harvested virus was then precipitated using PEG800 as described previously ([@bib35]) and resuspended in 10 mM HEPES, 150 mM NaCl. Huh-7.5 cells stably expressing firefly luciferase were seeded at a density of 2 × 10^4^ cells per well of a 96-well plate 24 hr prior to inoculation. CLR01 and CLR03 were diluted in 10 mM HEPES, 150 mM NaCl and incubated with Renilla luciferase reporter virus particles (JcR-2a) ([@bib66]; [@bib22]) for 5 min at 37°C. Cells were inoculated with JcR2-2a HCV in the presence of CLR01 or CLR03 for 72 hr at 37°C, washed with PBS, and lysed with 50 µl passive lysis buffer (Promega, Mannheim, Germany). To measure cytotoxicity, lysates were assayed for firefly luciferase activity using luciferin (200 µM luciferin, 25 mM glycylglycine, pH 8) in a plate luminometer (Lumat LB9507). For infectivity readout, lysates were assayed for Renilla luminescence using 1 µM coelenterazin (PJK, Kleinblittersdorf, Germany) in the same luminometer.

### Human adenovirus type 5 (HAdV5) {#s4-16-5}

The E1-deleted replication-deficient human adenovirus type 5-based vector containing a HCMV promoter-controlled EGFP expression cassette was produced on N52.E6 cells ([@bib70]), purified by one discontinuous and one continuous CsCl density gradient and subsequent size-exclusion chromatography (disposable PD-10, Amersham). The physical particle titer was determined by particle lysis and OD260 and confirmed by slot-blotting ([@bib33]). To assess effects of CLR01 and CLR03 on the ability of the vector to transduce cells, the vector was titrated with 0--100 µM CLR01 or CLR03 and incubated 10 min at 37°C in 50 mM HEPES, 150 mM NaCl, pH 7.4. 1 day prior to infection, 10^5^ A549 cells per well were seeded in a 24-well format. Cells were infected with 200 MOI of the pretreated virus. EGFP expression was analyzed using a Beckman--Coulter Gallios flow cytometer 1 day post transduction.

Impact of poly-L-lysine on the antiviral activity of CLR01 {#s4-17}
----------------------------------------------------------

R5-tropic HIV-1 NL4-3 92TH014 was treated with 40 µM CLR01 in the presence of buffer or increasing concentrations of poly-L-lysine (molecular weight 70,000--150,000 by viscosity) (0.3--75 nM). After a 10-min incubation, TZM-bl cells were infected and β-galactosidase activity was measured 2 days post infection.

Impact of coated BSA on the antiviral activity of CLR01 {#s4-18}
-------------------------------------------------------

Microtiter plates (96 well, flat bottom, Sarstedt 83.3924) were coated over night with 100 µl of 0, 0.2, 1 or 5% BSA dissolved in PBS at 4°C. After washing three times with PBS the coated wells were filled with 70 µl of 900 µM CLR01 and incubated 30 min at 37°C. Then, CLR01 was serially diluted and added to HIV-1 NL4-3 92TH014. Following a 10-min incubation, TZM-bl cells were infected and β-galactosidase activity was measured 2 days post infection.

Impact of free BSA on the antiviral activity of CLR01 {#s4-19}
-----------------------------------------------------

R5-tropic HIV-1 NL4-3 92TH014 was treated with 220 µM CLR01 in the presence of buffer or increasing concentrations of BSA (0.01--10%). After a 10-min incubation, TZM-bl cells were infected and β-galactosidase activity was measured 2 days post infection.

p24 release assay {#s4-20}
-----------------

HIV-1 NL4-3 92TH014 was incubated for 10 min at 37°C with PBS, 100 µM CLR03 or 100 µM CLR01 and centrifuged at 20,000×*g* and 4°C for 1 hr. The p24 content of the supernatant and pellet was determined using an in house p24-antigen ELISA.

Atomic force microscopy of virions {#s4-21}
----------------------------------

Virus solutions (20 µl) were deposited on aminopropyl-modified glass cover slips (AP-Glass) and incubated for 1 hr at room temperature. After removing excess liquid, the deposited virus particles were treated with 40 µl of 100 µM CLR01 or CLR03 and incubated for 10 min at RT. The samples were rinsed with PBS and imaged in PBS on a Nanowizard 3 AFM (JPK) in Quantitative Imaging mode using silicon nitride cantilevers with a spring constant of 0.03 N/m (Bruker, Billerica, MA).

Giant unilamellar vesicles {#s4-22}
--------------------------

Sodium dihydrogen phosphate, chloroform, and cholesterol (Chol) were purchased from Sigma--Aldrich. Lissamine rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (*N*-Rh-DHPE), ATTO 647 were purchased from Life Technologies and ATTO-TEC, respectively. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), sphingomyelin (SM), and 23-(dipyrrometheneboron difluoride)-24-norcholesterol (Bodipy-Chol) were purchased from Avanti Polar Lipids (Alabaster, AL). All chemicals used were of the highest analytical grade available and used without further purification.

Giant unilamellar vesicles (GUVs) were prepared by electroformation on optically transparent and electrically conductive indium tin oxide (ITO)-coated glass slides (SPI Supplies) in a preparation chamber consisting of a closed bath imaging chamber RC-21B affixed to a P-2 platform (both Warner Instruments Co.) topped with a flow-through temperature block. A solution of pure DOPC-containing 0.2 mol% *N*-Rh-DHPE or a lipid mixture of DOPC/SM/Chol (45/25/30 mol%) containing 0.2 mol% *N*-Rh-DHPE and 0.1 mol% Bodipy-Chol in chloroform was spread on an ITO-coated cover slip (20 μl, 1 mg/ml), spin-coated at 800 rpm for 1 min, and subsequently dried under vacuum for at least 2 hr. Afterwards, the lipids were hydrated in 10 mM NaH~2~PO~4~ pH 7.6, containing the water-soluble fluorophore ATTO 647 (5 μM) within the preparation chamber. The electroformation of pure DOPC and the DOPC/SM/cholesterol mixture was performed at room temperature and 60°C, respectively, by applying a frequency alternating current field (500 Hz, 100 mV for 10 min, 1 V for 20 min and 1.6 V for 2.5 hr) to the ITO electrodes by a function generator (Thurlby Thandar Instruments TG315). Afterwards, the preparation chamber was cooled down to room temperature in the case of the lipid mixture and carefully rinsed with 10 mM NaH~2~PO~4~ pH 7.6, to remove the water-soluble ATTO 647 that was not enclosed in the interior of the vesicles. Once a region of interest for imaging of the GUVs was chosen under the microscope, ∼500 µl of CLR01 (150 µM) in 10 mM NaH~2~PO~4~ pH 7.6, was added. Images were recorded by a confocal laser-scanning microscope (Biorad MRC 1024) coupled via a side port to an inverted microscope (Nikon; Eclipse TE-300DV) enabling fluorescence excitation in the focal plane of an objective lens (Nikon Plan Apo 60× WI, NA 1.2). Fluorescence of Bodipy-Chol, *N*-Rh-DHPE, and ATTO 647 was sequentially acquired by alternating the excitation with the 488, 568, and 647 nm lines of a Kr/Ar laser (Dynamic Laser, Salt Lake City, UT, USA). Signals were detected in three different PMT channels (emission band pass filters 522 nm/FWHM \[full width at half-maximum\] 35 nm, 580 nm/FWHM 32 nm, and 680 nm/FWHM 32 nm). Image acquisition was controlled by the software LaserSharp2000 (Biorad). Analysis of the data was performed using the software Fiji (Max Planck Society for the Advancement of Science e.V., Munich, Germany). Images were background and brightness/contrast corrected.

Atomic force microscopy of lipid bilayers {#s4-23}
-----------------------------------------

The phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and sphingomyelin (egg, chicken) (SM) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Sodium dihydrogen phosphate, chloroform, and cholesterol (Chol) were purchased from Sigma--Aldrich (Steinheim, BW, Germany). Stock solutions of 10 mg/ml lipids (DOPC, SM, Chol) in chloroform were dissolved to obtain 1.95 mg of total lipid with the composition of DOPC (100 mol%) and DOPC/SM/Chol (45/25/30 mol%) for the liquid AFM experiments. The majority of the chloroform was evaporated with a nitrogen stream and the rest of the solvent was removed afterwards by drying under vacuum overnight. The sodium dihydrogen phosphate buffer was filtered through filters of 0.02-µm pore size (Whatman, Dassel, Germany) before use. The dry lipid films were hydrated with 1 ml of 10 mM NaH~2~PO~4~, pH 7.6. Afterwards, the lipid mixtures were vortexed, kept in a water bath at 65°C for 15 min, and then sonicated for 10 min. After five freeze-thaw-vortex cycles and brief sonication, large multilamellar vesicles were formed and transformed to large unilamellar vesicles of uniform size by use of an extruder (Avanti Polar Lipids, Alabaster, USA) with polycarbonate membranes of 100 nm pore size at 65°C ([@bib88], [@bib87]). The vesicle fusion on mica was carried out by depositing 35 µl of the extruded lipid vesicle solution together with 35 µl of NaH~2~PO~4~ buffer on freshly cleaved mica and incubation in a wet chamber at 70°C for 2 hr. After the vesicle fusion, the samples were rinsed carefully with NaH~2~PO~4~ buffer to remove unspread vesicles. For the tweezer--membrane interaction studies, 800 µl of 150 µM CLR01 in NaH~2~PO~4~ buffer were slowly injected into the AFM fluid cell at room temperature and allowed to incubate for different time periods (1 min and 1 hr). Afterwards, the fluid cell was rinsed carefully with NaH~2~PO~4~ buffer before imaging to remove unbound tweezer. The measurements were performed on a MultiMode scanning probe microscope with a NanoScope IIIa controller (Bruker, Camarillo, CA, USA) and usage of a J-Scanner (scan size 125 µm). Images were obtained by applying the tapping mode in liquid with sharp nitride lever (SNL) probes mounted in a fluid cell (Bruker, Camarillo, CA, USA). Tips with nominal force constants of 0.24 N m^−1^ were used at driving frequencies around 9 kHz and drive amplitudes between 343 and 570 mV. Slow scan frequencies between 1.0 kHz and 1.97 kHz were required for high-resolution images. The height and phase images of sample regions were acquired with resolutions of 512 × 512 pixels. All AFM measurements were carried out at room temperature and the partitioning of the tweezer was analyzed by using analysis and NanoScope version 5 processing software ([@bib88], [@bib87]).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "A molecular tweezer antagonizes seminal amyloids and HIV infection" for consideration at *eLife*. Your article has been favorably evaluated by Randy Schekman (Senior editor) and three reviewers, one of whom, Jeffery W Kelly, is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

All reviewers concur that the significance of the work is potentially there. The concerns center around some of the data and critical control experiments relevant to the mechanism that seem to be missing.

All three reviewers expressed concerns centered around the mechanism of action of CRL01.

The authors postulate that classic host-guest complexes are forming whereas the reviewers suspect colloidal aggregation on the part of the CLR01 itself. Colloidal aggregation of organic small molecules can disrupt protein fibrils, by protein sequestration by the colloid (Feng et al., Nature Chem. Biol., 2008). Such a mechanism must be controlled for, especially given the peculiar efficacy of the compounds against the virion membranes themselves. Second, the authors should look to see if free lysine competes for CLR01 binding, disrupting its ability to act on the fibrils and the virions. There are few statistical analyses performed, so the relevance of comparing EC50 values is often unclear. On top of that, many of the raw data sets are of too low quality to produce accurate EC50 values, e.g. the lack of a saturation plateau. All three reviews are pasted below and the questions and suggestions in the reviews should be addressed if the authors choose to submit a revised manuscript.

*Reviewer \#1*:

These results appear to be incredible, and they may be. There are several critical controls that appear to be lacking, as indicated below. If the data hold up after these controls, then I am enthusiastic. Amyloid fibrils in seminal fluid composed of at least 4 cationic proteins are established to enhance HIV transmission through intercourse by binding virons augmenting fusion efficiency. The Lys-binding molecular tweezer CLR01 delays the aggregation of PAP248-286 and SEM1(45-107) fibrillization, half-maximal inhibitory concentrations (IC50) of CLR01 inhibition exhibited were 2.6 μM and 18.8 μM, respectively. By contrast, the IC50 to impede PAP85-120 assembly was significantly higher at 970 μM. Have the authors controlled for the possibility that CLR01 is functioning through colloid formation? It is important that the authors show that CLR01 is not impeding the adsorption of the aggregates to the EM grid, which can distort what is in solution. If these reactions are run for more than 30h, does aggregation into fibrils eventually occur? Does seeded aggregation eventually occur? The critical control that CLR01 is not displacing ThT from the fibrils needs to be performed. The analog in which all eight lysine and arginine residues are replaced by alanine appears to be far from a perfect control in that this variant is anticipated to be much more amyloidogenic? In [Figure 3](#fig3){ref-type="fig"}, the critical control that CLR01 is not displacing ThT from the fibrils and inhibiting fibril adsorption to the grids needs to be run-the rapidity of disassembly is surprising, is it really disassembly? The result that CLR01 destroys retroviral particles with IC50 values between 10-20 μM by compromising virion integrity further suggests that CLR01 might be functioning as a colloid. CLR01 decreased viral infectivity of semen in a concentration-dependent manner, while CLR03 had no impact on semen-mediated infection enhancement. At a CLR01 concentration of 31 μM, the enhancing effect of semen was completely abolished. Thus, CLR01 prevents HIV infection in the presence of semen. If this is occuring through monomeric CLR01 this is incredible, but I suspect the authors\' inhibitor is a micelle or colloid. The data are so impressive that I am concerned that these results are unlikely due to the monomeric molecular tweezer, but my hypothesis could be incorrect.

*Reviewer \#2*:

Seminal amyloids are known to concentrate HIV virions and enhance infectivity. In this report, the authors use a recently identified, general inhibitor of amyloid formation (the molecular tweezer CLR01) to understand whether it also inhibits model seminal amyloids: SEVI, PAP85-120 and SEM1. CLR01 is known to work by docking to exposed lysine and arginine residues and this molecule has found use as a probe for biophysical chemistry and protein folding studies. Lump et al. first test CLR01 as a possible inhibitor of seminal amyloids in vitro, using EM and a ThT assay. They then test whether the molecules can reverse pre-formed amyloids using similar methods. Next, they test whether CLR01 might block binding of mock virions to fibrils and find that the compound seems to disrupt virions themselves. They use AFM and microscopy in vesicles and virus particles to test this idea -- concluding that CLR01 seems to disrupt virion membranes, similar to a detergent. Somehow, this membrane disruption effect seems to be exclusive to viral membranes, but the mechanism remains cloudy (and somewhat confusing). They find that CLR01 blocks the infectivity-enhancing activity of seminal fibrils, both with and without addition of BSA. Based on these results, the possibility of using CLR01 for the prevention of viral spread are discussed. However, there are concerns (and even contradictions) about the lack of mechanistic knowledge and the nature of the CLR01-amyloid interaction is not well understood. The null hypotheses -- that CLR01 is a non-specific lysine interactor or even a detergent -- are not adequately tested. Without deeper mechanistic insight and more rigorous exploration of the binding events, publication of the work seems premature.

1\) There are few statistical analyses performed, so the relevance of comparing EC50 values is often unclear. On top of that, many of the raw data sets are of too low quality to produce accurate values. For example, the value of 970 uM ([Figure 2E](#fig2){ref-type="fig"}) has no saturation plateau, so one assumes that the value has a very large error. Similar problems can be seen in the raw data for [Figure 2F](#fig2){ref-type="fig"}, [Figure 2J](#fig2){ref-type="fig"}, [Figure 3G](#fig3){ref-type="fig"}, [Figure 3H](#fig3){ref-type="fig"} and all of [Figure 5](#fig5){ref-type="fig"}. These results cannot be adequately fit because of sparse datapoints, so comparing (or even reporting) the half-maximal values is not advised.

2\) One of the major problems with the manuscript is the uncertain mechanism of the compounds and the selectivity of the recognition. If CLR01 is simply blocking cationic charge of lysine and arginine residues, as the zeta potential and all-alanine mutant results imply, than one could presumably achieve this outcome faster, cheaper and more effectively with abundant biological polyanions, such as heparin or nucleic acids (DNA/RNA). What is the effect of these biological polyanions on the assembly of seminal amyloids and infectivity?

3\) The hypothesis of CLR01 binding to individual lysine and arginine residues is not experimentally tested outside of a rather crude comparison of an all-alanine replacement peptide (which likely doesn\'t conform to the same structure as the native peptide). Does free lysine, arginine or other free organic cations (or even divalent cations) compete for CLR01 binding? Does systematic replacements of lysine residues would provide insight into what the key interactions might be? What is the affinity of these interactions? Presumably there are countless free lysine residues in true seminal fluid, so how can CLR01 have the selectivity required to identify the seminal amyloids (especially given the rather weak EC50 values in the mid-micromolar)?

4\) The ability of the compounds to block fibril-induced virion activity in the presence of BSA doesn\'t appear to make logical sense. CLR01 was created as a general lysine/arginine probe -- so why wouldn\'t the compound be adsorbed onto the surface of BSA, which carries surface-exposed nucleophiles? The affinity of CLR01 for the seminal amyloid peptides and BSA (as a stand-in for biological fluids) needs to be carefully performed -- by NMR, ITC or other method.

5\) The lack of CLR01-induced toxicity in mammalian cells is confusing, given the effects on vesicles and virion membranes ([Figure 6](#fig6){ref-type="fig"}). The mammalian cells have numerous cholesterol-rich, raft-like domains, so that argument doesn\'t work. Presumably, the mammalian membranes would be disrupted just like in the vesicle and virion studies, but not leading to toxicity. What is going on here? Is calcium flux activated? Do the cells change shape? What is the affinity of CLR01 for viral membranes, vesicles and mammalian membranes? What lipid is being bound? By what mechanism do the membranes dissolve? Normally, such questions could be addressed in subsequent work, but the readers of this document would be expected to have major concerns about the logical gas and contradictions in the datasets, making careful and unbiased discussion an important requirement.

6\) What is the CMC equivalent of CLR01? In other words, at what concentration does it form micro-aggregates or micelles? Some (perhaps many?) of the observed activities could be a result of non-specific activities, as described by the Shoicet group. DLS studies and detergent competition experiments need to be performed.

*Reviewer \#3*:

Lump and colleagues describe the activity of a host-guest cavitand-like molecule, CLR01, in disassembling seminal protein fibrils and directly disrupting the membrane of HIV (and related) virions, much reducing HIV virus infectivity. The cavitand-like CLR01 acts by binding to lysine or arginine amino acids (the guests), with previously measured affinities in the 20 μM range, and presumably this activity is what leads to de-fibrilization (although exactly why binding should lead to defibrilization is unclear; presumably binding is improved in the soluble form, though this is not stated in the manuscript). In principle this is an interesting story, and certainly a novel use of a cavitand-like molecule, one that might inspire other efforts to repurpose such molecules, which are well-known to chemists, for similar effects. The manuscript could have substantial impact. Before it is published, I suggest the authors address the following concerns:

1\) My major concern regards the mechanism of action. The authors postulate that classic host-guest complexes are forming with the cationic amino acids, as shown in [Figure 1B](#fig1){ref-type="fig"}, and this is important to the specificity and ultimate usefulness of the compounds. Currently, however, the manuscript lacks two controls that would help establish this mechanism:

A\) First, the authors should control for colloidal aggregation on the part of the CLR01 itself. Colloidal aggregation of organic small molecules can disrupt protein fibrils, by protein sequestration in the small molecule colloid (Feng et al., Nature Chem. Biol., 2008). Such a mechanism must be controlled for, especially given the peculiar efficacy of the compounds against the virion membranes themselves (this is hard to square with a host-guest type interaction, but would make sense for colloidal aggregates). To do so, the authors should do one or more of the following i. Look to see if CLR01 is forming colloids in the 10 - 30 μM range, for instance by dynamic light scattering. ii. Add a mild, non-ionic detergent such as Tween-100 to disrupt the colloidal aggregates. This would right-shift the efficacy curves (assuming the detergent doesn\'t disrupt the fibrils directly). iii. Before addition to the fibrils, spin down the aqueous "solution" of CRL01 (not the DMSO one) in a microfuge at its highest speed for 20 minutes. Use the supernatant as the CLR01 solution for efficacy testing (colloids will typically pellet over this time). iv. Add 10 mg/ml BSA to the fibril mixture, before addition of CLR01. BSA will prophylacticly coat colloids, disrupting their actions.

B\) Second, the authors should look to see if free lysine competes for CLR01 binding, disrupting its ability to act on the fibrils and the virions. If it does not, or the effect is small, this would cast doubt on the mechanism proposed by the authors. This to me is an obvious control, and I worry that it was in the manuscript and I just overlooked it -- if I did I apologize. If not, it should be done.

Both controls should be done for both the effects on the protein fibrils and on the direct effects of the virus membrane. Whereas I hesitate to put authors to more work, I believe that these controls will substantially strengthen the manuscript, and should take more than a few days to perform.

2\) Minor points:

A\) I thought many of the dose response curves could be higher in quality, and should be re-done at better resolution.

B\) In the third paragraph of the subsection "CLR01 disaggregates preformed SEVI and PAP85-120 fibrils" the authors write that CLR01 acts sub-stoichiometrically. How do they know what the concentration of the relevant fibril species is? What is the stoichiometry?

C\) In the Discussion, the authors speculate on the use of CLR01 in vivo, as a drug or drug lead. Probably the only way such a molecule could be used is topically. It will not be orally absorbed (in all likelihood), and an intravenous route would lead to low compliance. If they are to speculate on this, as they do now, they should alert the readership to these points.

D\) I was unconvinced by the Concentration-Response curves, which are crucial to the efficacy arguments for CLR01. For [Figure 2D](#fig2){ref-type="fig"}, the curve should go through 0 (not 25%\...how is this possible at no compound?). More observations are needed in the transition region, and the authors should certainly sample every half-log, not every log10 in concentration. For [Figure 2J](#fig2){ref-type="fig"}, they should calculate a curve that actually goes through their points. I assume they fixed the Hill coefficient to 1, which doesn\'t seem to be supported by the curve. Here too, they need more points. In [Figure 5](#fig5){ref-type="fig"}, the Y-axis of the concentration-response curves should be on a linear scale, not a log scale. If it were, the reader would quickly notice that the curves are quite steep, which can be informative, and sometimes concerning.

Notwithstanding these concerns, the manuscript is interesting and could have wide impact. If the authors can address the concerns of the missing controls, I would support its publication.

10.7554/eLife.05397.031

Author response

*All reviewers concur that the significance of the work is potentially there. The concerns center around some of the data and critical control experiments relevant to the mechanism that seem to be missing*.

*All three reviewers expressed concerns centered around the mechanism of action of CRL01*.

*The authors postulate that classic host-guest complexes are forming whereas the reviewers suspect colloidal aggregation on the part of the CLR01 itself. Colloidal aggregation of organic small molecules can disrupt protein fibrils, by protein sequestration by the colloid (Feng et al., Nature Chem. Biol., 2008). Such a mechanism must be controlled for, especially given the peculiar efficacy of the compounds against the virion membranes themselves*.

We thank the editor and reviewers for raising this issue. We agree that it is critical to exclude the possibility that CLR01 is acting via a non-specific mechanism that involves colloidal CLR01 aggregates. Colloidal aggregates formed by certain organic small molecules can inhibit fibril assembly by various amyloidogenic proteins, but to the best of our knowledge have not been reported to disrupt preformed amyloid fibrils (also mentioned by reviewer 3) ([@bib14]). Furthermore, in all our experiments performed with CLR01 during the past 8 years, no hint of colloidal aggregate formation has been found.

Here, to rule out any participation of colloidal aggregates, we performed five independent experiments to assess potential aggregate formation by CLR01 (documented and discussed in detail in the revised manuscript (subsection "CLR01 does not form colloidal aggregates"), new [Figure 7](#fig7){ref-type="fig"}). All experiments were performed in exactly the same buffer compositions as used in the manuscript:

1\) NMR dilution titrations provided experimental evidence for a very weak CLR01 dimer formation (K~a~ = ∼60M^-1^) in PBS buffer (10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4), with ∼5% CLR01 dimers present at 500 µM ([Figure 7A](#fig7){ref-type="fig"}; [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}). Dimerization was totally absent in HEPES buffer (25 mM HEPES, 150 mM KOAc, 10 mM Mg(OAc)~2~, pH 7.4) ([Figure 7B](#fig7){ref-type="fig"}; [Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}). Thus, CLR01 is predominantly monomeric.

2\) Diffusion NMR (DOSY) experiments in both buffers revealed hydrodynamic radii of ∼0.9 to 1.0 nm, slightly above the monomeric species ([Figure 7C, 7D](#fig7){ref-type="fig"}; [Figure 7--figure supplement 3](#fig7s3){ref-type="fig"}).

3\) Microcalorimetric dilution titrations revealed only minute endothermic heat changes, strongly contradicting an extensive aggregation process (data not shown).

4\) Pyrene fluorescence revealed that no critical micelle concentration (cmc) could be determined in a wide concentration range (0-500 µM CLR01) encompassing fibril assembly and remodeling conditions ([Figure 7E](#fig7){ref-type="fig"}).

5\) Dynamic Light Scattering (DLS), which overemphasizes the presence of large aggregates because the intensity of the scattered light is proportional to the square of the mass, revealed a very small fraction of CLR01 formed particles with hydrodynamic radius *R*~*H*~ ∼5--8 nm in PBS at concentration between 200--1,000 μM, plus a very minor fraction of particles with a *R*~*H*~ ∼ 20--40 nm ([Figure 7F](#fig7){ref-type="fig"}). We did not observe CLR01 particles with an *R*~*H*~ of ∼95-400 nm, which is the size range typically associated with colloidal small-molecule aggregates ([@bib43]). By contrast, no CLR01 particles could be detected at 10 or 50 μM in PBS (data not shown). Moreover, no CLR01 particles were detected in HEPES buffer up to 1 mM ([Figure 7F](#fig7){ref-type="fig"}).

Thus, under all assay concentrations the vast majority of the tweezer molecules are monomeric. Minute amounts of dimers or higher order species may be present at high concentrations of CLR01 in some cases in PBS buffer (fibril assembly and cell culture buffer), but are absent from the HEPES buffer (fibril remodeling buffer). Thus, it is highly unlikely that colloidal CLR01 aggregates contribute meaningfully to the observed activity of the compound.

We have also performed experiments to exclude the possibility that the minute quantities of CLR01 that might form colloidal aggregates were the active species. Thus, the ability of CLR01 to: (a) inhibit fibril assembly by PAP248-286, PAP85-120, and SEM1(45-107); (b) remodel preformed SEVI and PAP85-120 fibrils; and (c) directly inhibit HIV infection (in the absence of seminal amyloid) was not affected by:

1\) BSA (10-50mg/ml), which would adsorb to the surface of any colloidal CLR01 aggregates and quench their activity ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5--figure supplement 2 and 3](#fig5s2 fig5s3){ref-type="fig"}; [Figure 9A](#fig9){ref-type="fig"}) ([@bib14]; [@bib43]).

2\) Preclearing buffers containing CLR01 by centrifugation at 16,100-20,000g for 20min, which would remove any colloidal CLR01 aggregates ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5--figure supplement 4](#fig5s4){ref-type="fig"}) ([@bib44]).

These data strongly suggest that the small quantities of colloidal CLR01 aggregates that might be present are not the active species.

Finally, a feature of small molecules that form colloidal aggregates is that they are non-specific inhibitors ([@bib14]; [@bib43]; [@bib44]). By contrast, however, CLR01 displays specificity for amyloidogenesis by peptides that harbor lysine and arginine residues. Thus, if the lysine and arginine residues of PAP248-286 or PAP85-120 are replaced with alanine, then CLR01 can neither inhibit fibril assembly nor remodel preformed fibrils ([Figure 2-I, 3I-L](#fig2 fig3){ref-type="fig"}). This specificity is not consistent with an indiscriminate, non-specific mechanism of action mediated by colloidal CLR01 aggregates.

*Second, the authors should look to see if free lysine competes for CLR01 binding, disrupting its ability to act on the fibrils and the virions*.

We have now established that free lysine or poly-L-lysine disrupt the anti-amyloid and antiviral activities of CLR01 ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}; [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}; [Figure 4--figure supplement 1;](#fig4s1){ref-type="fig"} [Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}). These data provide further support that the lysine-binding cavity of CLR01 plays an important role in both the anti-amyloid and antiviral activities of CLR01.

*There are few statistical analyses performed, so the relevance of comparing EC50 values is often unclear. On top of that, many of the raw data sets are of too low quality to produce accurate EC50 values, e.g. the lack of a saturation plateau*.

We have now included additional replicates and tested additional concentrations of CLR01 to improve the accuracy of our IC~50~ and EC~50~ measurements ([Figure 2D, E, F, L, 3G, H](#fig2 fig3){ref-type="fig"}). We now also qualify differences with statistics where appropriate throughout the manuscript ([Figure 2--figure supplement 1, 3-5](#fig2s1 fig2s3 fig2s4 fig2s5){ref-type="fig"}; [Figure 3--figure supplement 1, 2](#fig3s1 fig3s2){ref-type="fig"}; [Figure 5--figure supplement 1, 3 and 4](#fig5s1 fig5s3 fig5s4){ref-type="fig"}; [Figure 6A and 6B](#fig6){ref-type="fig"}; [Figure 8A-D](#fig8){ref-type="fig"}; [Figure 9A, B](#fig9){ref-type="fig"}).

Reviewer \#1:

*These results appear to be incredible, and they may be. There are several critical controls that appear to be lacking, as indicated below. If the data hold up after these controls, then I am enthusiastic. Amyloid fibrils in seminal fluid composed of at least 4 cationic proteins are established to enhance HIV transmission through intercourse by binding virons augmenting fusion efficiency. The Lys-binding molecular tweezer CLR01 delays the aggregation of PAP248-286 and SEM1(45-107) fibrillization, half-maximal inhibitory concentrations (IC50) of CLR01 inhibition exhibited were 2.6 μM and 18.8 μM, respectively. By contrast, the IC50 to impede PAP85-120 assembly was significantly higher at 970 μM. Have the authors controlled for the possibility that CLR01 is functioning through colloid formation*?

As outlined above in response to editor, we now provide evidence that CLR01 is not functioning through colloidal aggregate formation.

*It is important that the authors show that CLR01 is not impeding the adsorption of the aggregates to the EM grid, which can distort what is in solution*.

The reviewer raises a good point. When we mix CLR01 (or buffer) with preformed SEVI, PAP85-120, or SEM1(45-107) fibrils for 10 min (a time at which no fibril remodeling occurs; [Figure 3A-C](#fig3){ref-type="fig"}) and then adsorb them to the EM grid, we observe abundant fibrils in both the CLR01 and buffer control conditions ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}). Furthermore, it is evident in [Figure 3C](#fig3){ref-type="fig"}, that CLR01 does not affect adsorption of SEM1(45-107) fibrils to the EM grid. Collectively, these observations strongly suggest that CLR01 does not impede adsorption of peptide conformers to the grid.

*If these reactions are run for more than 30h, does aggregation into fibrils eventually occur? Does seeded aggregation eventually occur*?

We have run the spontaneously fibril assembly reactions for 68 h for PAP248-286 ([Figure 2A](#fig2){ref-type="fig"}) and 72 h for SEM1(45-107) ([Figure 2C](#fig2){ref-type="fig"}) and observe very little fibril assembly in the presence of CLR01. We have now also run the PAP85-120 fibril assembly reaction for 68 h and observe very little fibril assembly in the presence of CLR01 ([Figure 2B](#fig2){ref-type="fig"}). Thus, under these conditions CLR01 is a potent inhibitor, which prevents spontaneous PAP248-286, PAP85-120, and SEM1(45-107) fibril assembly.

*The critical control that CLR01 is not displacing ThT from the fibrils needs to be performed*.

We thank the reviewer for suggesting this key control. We have addressed this question in two ways. First, we have monitored early time points (0 min, 10 min and 20 min) in SEVI and PAP85-120 fibril remodeling by CLR01 ([Figure 3A, B](#fig3){ref-type="fig"}). At these times, robust ThT fluorescence is still observed indicating that CLR01 is not simply displacing ThT from SEVI or PAP85-120 fibrils. Indeed, fibrils are still prevalent at these early times ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}). Thus, CLR01 is not simply competing for ThT binding as we would expect an instantaneous effect on ThT fluorescence as is observed, for example, with another small molecule EGCG and ABeta40 fibrils (Palhano et al., 2013). In this regard, it is also important to note that ThT fluorescence of SEM1(45-107), SEVI(Ala), and PAP85-120(Ala) fibrils is unaffected by CLR01 at various times ([Figure 3C, 3I, 3L](#fig3){ref-type="fig"}). Thus, CLR01 is not a general inhibitor or competitor of ThT binding to amyloid fibrils.

In a second approach, we employed a ThT displacement assay ([@bib36]). Here, preformed SEVI, PAP85-120, or SEM1(45-107) fibrils (5 µM monomer) were preincubated with ThT (25 µM) for 30min at room temperature. Buffer, CLR01 (250 µM), or a known competitor of ThT binding, BTA-1 (250 µM) ([@bib36]) were then added and incubated for 10min at room temperature. ThT displacement was then assessed by fluorescence. BTA-1 effectively displaced ThT, whereas CLR01 did not ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). These findings establish that CLR01 does not simply displace ThT from SEVI, PAP85-120, or SEM1(45-107) fibrils. Thus, any reduction in ThT fluorescence caused by CLR01 can be attributed to an inhibition of fibril assembly or remodeling of fibrils into conformers unable to bind ThT. Inhibition of fibril assembly by CLR01 has also been assessed by EM ([Figure 2A-C](#fig2){ref-type="fig"}). Likewise, fibril remodeling by CLR01 has also been assessed by: EM ([Figure 3A-C](#fig3){ref-type="fig"}), Proteostat staining, a red fluorescent aggregate sensing dye ([Figure 3A-C](#fig3){ref-type="fig"}), seeding activity of remodeled conformers ([Figure 3F](#fig3){ref-type="fig"}), and circular dichroism ([Figure 3D, E](#fig3){ref-type="fig"}). By employing multiple approaches, we thus establish that CLR01 inhibits amyloid assembly of PAP248-286, PAP85-120, and SEM1(45-107), and remodels preformed SEVI and PAP85-120 fibrils.

*The analog in which all eight lysine and arginine residues are replaced by alanine appears to be far from a perfect control in that this variant is anticipated to be much more amyloidogenic*?

We have demonstrated that PAP248-286(Ala) and now the PAP85-120(Ala) peptide readily assemble into ThT-reactive fibrils in the presence of CLR01 ([Figure 2G-I](#fig2){ref-type="fig"}). Moreover, SEVI(Ala) and PAP85-120(Ala) fibrils are resistant to remodeling by CLR01 ([Figure 3I-L](#fig3){ref-type="fig"}). Thus, the activity of CLR01 cannot be attributed to a general ability to displace ThT from fibrils (and see above response). Indeed, CLR01 also has no effect on the ThT fluorescence of preformed SEM1(45-107) fibrils ([Figure 3C](#fig3){ref-type="fig"}). Rather, the PAP248-286(Ala) and PAP85-120(Ala) results suggest that CLR01 is unable to inhibit fibrillization or remodel fibrils when the target polypeptide is devoid of lysine and arginine residues. The PAP248-286(Ala) and PAP85-120(Ala) peptides spontaneously assemble into amyloid more rapidly than the wild-type peptides ([Figure 2A, B, G, I](#fig2){ref-type="fig"}). However, we have been unable to establish conditions (e.g. higher CLR01 concentrations) where CLR01 prevents assembly of PAP248-286(Ala) and PAP85-120(Ala) into amyloid fibrils. Likewise, we have been unable to establish conditions (e.g. higher CLR01 concentrations) where CLR01 remodels SEVI(Ala) or PAP85-120(Ala) fibrils. These results are consistent with our suggestion that CLR01 is inactive against polypeptides devoid of lysine or arginine residues.

*In* [*Figure 3*](#fig3){ref-type="fig"}*, the critical control that CLR01 is not displacing ThT from the fibrils and inhibiting fibril adsorption to the grids needs to be run-the rapidity of disassembly is surprising, is it really disassembly*?

As discussed above, we have demonstrated that CLR01 does not affect amyloid adsorption to EM grids ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}) or displace ThT from fibrils ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). Although rapid, we now show that fibril remodeling by CLR01 is not instantaneous. Indeed, SEVI and PAP85-120 fibrils resist remodeling for ∼20 min ([Figure 3A, B](#fig3){ref-type="fig"}). However, to be more cautious we now avoid the term fibril disassembly, and instead use the term fibril remodeling, which more accurately describes the observed effects.

*The result that CLR01 destroys retroviral particles with IC50 values between 10-20 μM by compromising virion integrity further suggests that CLR01 might be functioning as a colloid. CLR01 decreased viral infectivity of semen in a concentration-dependent manner, while CLR03 had no impact on semen-mediated infection enhancement. At a CLR01 concentration of 31 μM, the enhancing effect of semen was completely abolished. Thus, CLR01 prevents HIV infection in the presence of semen. If this is occuring through monomeric CLR01 this is incredible, but I suspect the authors\' inhibitor is a micelle or colloid. The data are so impressive that I am concerned that these results are unlikely due to the monomeric molecular tweezer, but my hypothesis could be incorrect*.

As outlined in the response to the editor, CLR01 does not form colloids, micelles, or other large aggregates ([Figure 7](#fig7){ref-type="fig"}). We agree that the µM activity of CLR01 against HIV-1 in the presence of semen is remarkable. However, this is not due to formation of colloidal CLR01 aggregates as human seminal fluid contains abundant quantities of protein, which would be anticipated to quench the activity of a non-specific colloidal aggregate by adsorption ([@bib14]). Moreover, CLR01 activity against the virus is preserved in the presence of BSA (10 mg/ml; [Figure 5--figure supplement 2 and 3](#fig5s2 fig5s3){ref-type="fig"}) and is retained in the soluble fraction after centrifugation of CLR01 ([Figure 5--figure supplement 4](#fig5s4){ref-type="fig"}), two established methods to eliminate the activity of non-specific small molecule colloids ([@bib14]). Furthermore, CLR01 exerts powerful inhibitory effects on amyloid accumulation of Abeta and TTR in vivo in mouse models ([@bib5]; [@bib15]) and alpha-synuclein aggregation in zebrafish models ([@bib64]). This potent activity in vivo makes a colloidal-based mechanism extremely unlikely. Taken together, these data suggest that CLR01 is not acting via a mechanism involving non-specific colloidal CLR01 aggregates.

Reviewer \#2:

*\[... The authors\] find that CLR01 blocks the infectivity-enhancing activity of seminal fibrils, both with and without addition of BSA. Based on these results, the possibility of using CLR01 for the prevention of viral spread are discussed. However, there are concerns (and even contradictions) about the lack of mechanistic knowledge and the nature of the CLR01-amyloid interaction is not well understood. The null hypotheses -- that CLR01 is a non-specific lysine interactor or even a detergent -- are not adequately tested. Without deeper mechanistic insight and more rigorous exploration of the binding events, publication of the work seems premature*.

We agree that further mechanistic insight would enhance our study. Hence, we have now added several experiments that provide deeper insight into the mechanism of CLR01 action. We can now exclude the possibility that CLR01 is acting via a non-specific mechanism mediated by colloidal CLR01 aggregates or detergent-like CLR01 micelles (see response to editor). We also demonstrate that the lysine-binding cavity of CLR01 plays an important role in both the anti-amyloid and antiviral activities of CLR01 ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}; [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}; [Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}). Indeed, it is important to note that the specificity of CLR01 binding to lysine or arginine is well established. CLR01 was tested against almost all naturally occurring amino acid residues in model compounds, and does not bind to any other amino acid side chain except for lysine (*K*~*d*~∼10 µM) and arginine (*K*~*d*~∼50 µM) ([@bib16]; [@bib29]; [@bib31]). The structure of the CLR01-lysine complex and the precise mechanism of lysine threading into the CLR01 guest cavity and subsequent ion pairing have been extensively characterized by NMR spectroscopy, crystal structure, molecular dynamics, and quantum mechanics/molecular mechanics (QM/MM) calculations ([@bib6]; [@bib13]; [@bib30]). Importantly, CLR01 has no effect on formation or remodeling of SEVI(Ala) or PAP85-120(Ala) fibrils in which all lysine and arginines residues are exchanged to alanines ([Figure 2G-I, 3I-L](#fig2 fig3){ref-type="fig"}). Thus, CLR01 does not inhibit amyloid formation or remodel amyloid fibrils in a non-specific way but rather requires that the polypeptides bear arginine or lysine residues. Moreover, the presence of arginine or lysine residues in the target peptide also does not guarantee that CLR01 will be able to remodel amyloid fibrils. Indeed, CLR01 could not remodel preformed SEM1(45-107) fibrils ([Figure 3C](#fig3){ref-type="fig"}), indicating a specific effect of CLR01 on SEVI and PAP85-120 fibrils ([Figure 3A, B](#fig3){ref-type="fig"}). Importantly, we now also show that free lysine or poly-L-lysine abrogate the anti-amyloid activity of CLR01, further demonstrating specificity ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}; [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}; [Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}). Moreover, CLR01 does not exert cytotoxic effects on cells, unlike non-ionic and anionic detergents such as TX-100, nonoxyl 9, or SDS ([Figure 4--figure supplement 3](#fig4s3){ref-type="fig"}). Collectively, these data establish that CLR01 is not acting in a non-specific manner that involves detergent-like CLR01 micelles.

*1) There are few statistical analyses performed, so the relevance of comparing EC50 values is often unclear. On top of that, many of the raw data sets are of too low quality to produce accurate values. For example, the value of 970 uM (*[*Figure 2E*](#fig2){ref-type="fig"}*) has no saturation plateau, so one assumes that the value has a very large error. Similar problems can be seen in the raw data for* [*Figure 2F*](#fig2){ref-type="fig"}*,* [*Figure 2J*](#fig2){ref-type="fig"}*,* [*Figure 3G*](#fig3){ref-type="fig"}*,* [*Figure 3H*](#fig3){ref-type="fig"} *and all of* [*Figure 5*](#fig5){ref-type="fig"}*. These results cannot be adequately fit because of sparse datapoints, so comparing (or even reporting) the half-maximal values is not advised*.

We have now included additional replicates and tested additional concentrations of CLR01 to improve the accuracy of our IC~50~ and EC~50~ measurements ([Figure 2D, E, F, L, 3G, H](#fig2 fig3){ref-type="fig"}). We now also qualify differences with statistics where appropriate throughout the manuscript ([Figure 2--figure supplement 1, 3-5](#fig2s1 fig2s3 fig2s4 fig2s5){ref-type="fig"}; [Figure 3--figure supplement 1,2](#fig3s1 fig3s2){ref-type="fig"}; [Figure 5--figure supplement 1, 3 and 4](#fig5s1 fig5s3 fig5s4){ref-type="fig"}; [Figure 6A and 6B](#fig6){ref-type="fig"}; [Figure 8A-D](#fig8){ref-type="fig"}; [Figure 9A, B](#fig9){ref-type="fig"}).

The data shown in [Figure 5](#fig5){ref-type="fig"} were derived from triplicate infections with seven different concentrations of the tweezer including controls (infected and uninfected cells). The inhibition curve follows a typical sigmoidal shape and thus allows a meaningful determination of IC~50~ values using Graphpad Prism software~.~ We have extensive experience in the determination of antiviral activities and IC~50~ values, including the preclinical and clinical development of drugs (Forssmann et al., 2010; [@bib51]; Venken et al., 2011; [@bib96]; Zirafi et al., 2015).

*2) One of the major problems with the manuscript is the uncertain mechanism of the compounds and the selectivity of the recognition. If CLR01 is simply blocking cationic charge of lysine and arginine residues, as the zeta potential and all-alanine mutant results imply, than one could presumably achieve this outcome faster, cheaper and more effectively with abundant biological polyanions, such as heparin or nucleic acids (DNA/RNA). What is the effect of these biological polyanions on the assembly of seminal amyloids and infectivity*?

The reviewer raises an interesting point. However, it is important to note that CLR01 and CLR03 have identical negative charge, but only CLR01 exerts an anti-amyloid or antiviral effect ([Figure 2A-C, 3A-C, 5A, 6A, 8A-C, 9A, B](#fig2 fig3 fig5 fig6 fig8 fig9){ref-type="fig"}). We can therefore exclude the possibility that the effects of CLR01 are a trivial consequence of being anionic. Simply being anionic is not sufficient for anti-amyloid or antiviral activity, as CLR03 lacks activity ([Figure 2A-C, 3A-C, 5A, 6A, 8A-C, 9A, B](#fig2 fig3 fig5 fig6 fig8 fig9){ref-type="fig"}). This can be rationalized by the fact that, at the molecular level, the interaction of CLR01 with Lys residues is based on the formation of inclusion complexes in which Lys is trapped inside the tweezer's cavity ([@bib6]; [@bib13]). The chemical structure of CLR03 does not allow for the formation of such inclusion complexes. Thus, as shown by the simulations reported in this paper, CLR03 interactions with the Lys residues of PAP are not preserved, unlike CLR01, which forms conserved inclusion complexes ([Figure 1F, G](#fig1){ref-type="fig"}).

With regard to the effect of biological polyanions on HIV infectivity, it is well established that heparin (Ito et al., 1987; Rider, 1997; Vives et al., 2005) or oligodeoxynucleotides (Matsukura et al., 1987; Stein et al., 1993; Vaillant et al., 2006) can inhibit HIV-1 infection by binding to viral envelope glycoproteins, cellular receptors, or both. By contrast, CLR01 directly disrupts the viral membrane thereby eliminating the virus ([Figure 6A-D](#fig6){ref-type="fig"}). Hence, CLR01 and polyanions directly inhibit HIV infection by very different mechanisms.

It has also been demonstrated that heparin binds SEVI or PAP85-120 fibrils by electrostatic interactions, rendering the fibril surface negatively charged, thereby preventing enhancement of HIV infection ([@bib3]; [@bib69]). Even though CLR01 is also negatively charged, it binds to SEVI, PAP85-120, or SEM1(49-107) fibrils via specific interaction with lysine or arginine residues making the fibrils neutrally charged ([Figure 4A](#fig4){ref-type="fig"}). In addition, CLR01 prevents SEVI, PAP85-120, or SEM1(45-107) fibril formation ([Figure 2A-C](#fig2){ref-type="fig"}) and remodels preformed SEVI and PAP85-120 fibrils ([Figure 3A, B](#fig3){ref-type="fig"}), whereas polyanions such as heparin accelerate the formation of SEVI fibrils (Tan et al., 2013). Thus, CLR01 and polyanions inhibit the viral infection enhancing activity of amyloids fibrils by different mechanisms.

Polyanions, including heparin and various other glycosaminoglycans, have been investigated as HIV microbicides for decades, as they are also thought to exert direct anti-HIV activity by inhibiting the binding of the viral envelope glycoprotein, gp120, to its major cell surface receptor CD4 (Callahan et al., 1991; Rider, 1997; Witvrouw and De Clercq, 1997). Unfortunately, such anionic polymers have proven to be unsuccessful in past clinical trials due to their poor bioavailability and induction of inflammatory responses in the genital tract, which instead augment HIV transmission by recruiting HIV-susceptible target cells to the genital mucosa ([@bib40]; [@bib83]). Moreover, it has recently become clear that the HIV-enhancing activity of semen diminishes the efficacy of diverse anti-HIV microbicides, including several polyanions ([@bib96]). By contrast, CLR01 retains potent antiviral activity in the presence of semen ([Figure 9B](#fig9){ref-type="fig"}). Thus, CLR01 antagonizes seminal amyloid and HIV via distinct mechanisms to polyanions and retains high activity in semen, which is likely an advantageous property for a potential microbicide candidate. We now discuss some of these issues in the Discussion.

*3) The hypothesis of CLR01 binding to individual lysine and arginine residues is not experimentally tested outside of a rather crude comparison of an all-alanine replacement peptide (which likely doesn\'t conform to the same structure as the native peptide)*.

We have established that CLR01 is ineffective in preventing amyloid formation by PAP248-286(Ala) ([Figure 2G, H](#fig2){ref-type="fig"}), and is also unable to remodel preformed SEVI(Ala) fibrils ([Figure 3I-K](#fig3){ref-type="fig"}). We have now extended these experiments to a PAP85-120 peptide, PAP85-120(Ala), where all the lysines and arginines are replaced by alanine. CLR01 is unable to inhibit the amyloidogenesis of PAP85-120(Ala) ([Figure 2I](#fig2){ref-type="fig"}) and is unable to remodel preformed PAP85-120(Ala) fibrils ([Figure 3L](#fig3){ref-type="fig"}). These findings strongly suggest that lysine and arginine residues are critical for CLR01 activity against PAP248-286 and PAP85-120.

It is important to note that it is well established that CLR01 selectively binds lysine in amyloid fibrils ([@bib1]; [@bib5]; [@bib15]; [@bib64]; [@bib74]; [@bib75]; [@bib95]). We have examined several complexes between CLR01 and peptides/proteins with multiple lysines ([@bib16]; [@bib29]; [@bib31]). 2D NMR and MS experiments have revealed, for example, that the tweezer molecule sits exclusively on both lysines and to a smaller extent on the single arginine of Αβ1-40 ([@bib75]). In addition, we have shown that some enzymes with lysine residues around the active site can be inhibited by CLR01, and start to work again, after addition of free lysine ([@bib78]). As mentioned above, the interaction between CLR01 and lysine has been studied and it is structurally well characterized: threading of the lysine side chain through the tweezer cavity, plus ion pair formation between the lysine ammonium cation and the tweezer phosphate anion produces a *K*~*d*~ of ∼10 µM for the 1:1 complex between one lysine side chain and one tweezer molecule, as determined by NMR and fluorescence titration ([@bib6]; [@bib30]; [@bib37]). Collectively, these precedents provide further support for a critical role for CLR01 interactions with lysine or arginine residues in the effects we observe on seminal amyloid peptides.

*Does free lysine, arginine or other free organic cations (or even divalent cations) compete for CLR01 binding*?

To provide evidence that the anti-amyloid activity of CLR01 depends on the specific interaction with lysine, we performed competition experiments with free lysine or poly-L-lysine. As now shown in the revised manuscript, pretreatment of CLR01 with free lysine or poly-L-lysine abrogates the tweezers' ability to: block amyloid formation ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}), remodel amyloid ([Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}), neutralize amyloid surface charge ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}), and directly antagonize viral infection ([Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}).

*Does systematic replacements of lysine residues would provide insight into what the key interactions might be? What is the affinity of these interactions*?

The reviewer makes great suggestions here. It will be extremely interesting to systematically replace the various lysine and arginine residues in PAP248-286, PAP85-120, and SEM1(45-107) to determine which lysines or arginines are critical for CLR01 to prevent amyloid assembly by these peptides. Likewise, it will be very interesting to systematically replace the various lysine and arginine residues in PAP248-286 and PAP85-120 to determine which are critical for fibril remodeling by CLR01. How these alterations affect the affinity of CLR01 for the various peptides will also be very interesting to determine. However, this is a very large set of studies, which we suggest is beyond the scope of this initial manuscript. We plan to perform these for a separate study where we dissect CLR01 mechanism in further detail.

*Presumably there are countless free lysine residues in true seminal fluid, so how can CLR01 have the selectivity required to identify the seminal amyloids (especially given the rather weak EC50 values in the mid-micromolar)*?

The reviewer raises a very interesting point. The interaction between a single lysine residue and CLR01 has a *K*~*d*~ of ∼10µM, with fast on and off rates. On proteins, however, only a few lysines are well accessible for the relatively large molecular skeleton of the tweezers. For example, ITC and MD+QM/MM calculations have revealed that only 5 of 17 surface lysines in a 14-3-3 protein are complexed by CLR01 ([@bib6]). In addition, a key point is that, because of the high on--off rate, CLR01 disrupts only relatively weak interactions as well as events that depend on critical and accessible lysine or arginine residues. Therefore, the tweezer has shown selectivity in multiple cases that on first impression may appear counter-intuitive. For example, inhibition of abnormal protein aggregation is achieved at 1:1--1:5 protein:CLR01 concentration ([@bib1]; [@bib74]; [@bib75]), whereas disruption of controlled protein polymerization, e.g., of tubulin, requires 55-fold excess CLR01 ([@bib4]) and enzyme inhibition requires ∼1,000-fold excess CLR01 ([@bib78]). Moreover, in vivo, CLR01 shows no toxicity at doses 2--3 orders of magnitude above those needed to enable clearance of amyloid ([@bib4]; [@bib5]; [@bib15]; [@bib64]). Thus, selectivity for lysine-bearing amyloid conformers in complex biological fluids is achieved by CLR01. We now discuss the issue (Discussion).

To experimentally address this question, we have tested the effect of BSA on the ability of the tweezer to antagonize virus infection. Neither coated nor free BSA affected the antiviral activity of CLR01 ([Figure 5--figure supplements 2 and 3](#fig5s2 fig5s3){ref-type="fig"}). Of note, all cell culture experiments ([Figure 4G, 5A, 8A-C, 9B](#fig4 fig5 fig8 fig9){ref-type="fig"}) were performed in the presence of 10% FCS which contains abundant proteins, further demonstrating that free lysines at the surface of bulk, structured proteins do not affect CLR01 function. Likewise, CLR01 retains antiviral activity in the presence of seminal fluid ([Figure 9B](#fig9){ref-type="fig"}), which also contains abundant proteins bearing lysine residues. Moreover, inhibition of amyloid assembly or amyloid remodeling by CLR01 was unaffected by BSA, indicating that surface lysines and arginines on BSA are not effective competitors of CLR01 activity ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}).

*4) The ability of the compounds to block fibril-induced virion activity in the presence of BSA doesn\'t appear to make logical sense. CLR01 was created as a general lysine/arginine probe -- so why wouldn\'t the compound be adsorbed onto the surface of BSA, which carries surface-exposed nucleophiles? The affinity of CLR01 for the seminal amyloid peptides and BSA (as a stand-in for biological fluids) needs to be carefully performed -- by NMR, ITC or other method*.

There is a profound difference between freely accessible lysines on non-structured protein domains, which can all be complexed by the tweezers, and folded proteins, whose surface often does not allow the sterically-demanding tweezer molecule to approach a lysine residue close enough for the threading mechanism. The interaction of CLR01 with seminal fibrils has been discussed above. To experimentally address whether BSA affects the antiviral activity of the tweezer and its ability to antagonize fibril-mediated infectivity enhancement (the two main mechanisms to prevent sexual viral transmission) we performed competition experiments. As mentioned above, we found that physiologically relevant concentrations of coated or free BSA do not affect the direct antiviral activity of CLR01 ([Figure 5--figure supplements 2 and 3](#fig5s2 fig5s3){ref-type="fig"}). These results are in agreement with our previous data showing that the tweezer is active in the presence of semen ([Figure 9B](#fig9){ref-type="fig"}). BSA also failed to antagonize inhibition of amyloid assembly or amyloid remodeling by CLR01, suggesting that surface lysines and arginines on BSA are ineffective competitors of CLR01 ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}).

*5) The lack of CLR01-induced toxicity in mammalian cells is confusing, given the effects on vesicles and virion membranes (*[*Figure 6*](#fig6){ref-type="fig"}*). The mammalian cells have numerous cholesterol-rich, raft-like domains, so that argument doesn\'t work. Presumably, the mammalian membranes would be disrupted just like in the vesicle and virion studies, but not leading to toxicity. What is going on here? Is calcium flux activated? Do the cells change shape? What is the affinity of CLR01 for viral membranes, vesicles and mammalian membranes? What lipid is being bound? By what mechanism do the membranes dissolve? Normally, such questions could be addressed in subsequent work, but the readers of this document would be expected to have major concerns about the logical gas and contradictions in the datasets, making careful and unbiased discussion an important requirement*.

As mentioned by the reviewer, we suggest that a thorough analysis of the interaction of the tweezer with cellular and viral membranes is beyond the scope of this study. We like to point out, however, that we have extensively studied possible cytotoxic effects of CLR01 in vitro and in vivo, but have never observed significant effects at concentrations up to 500 µM ([Figure 4--figure supplement 3](#fig4s3){ref-type="fig"}). We now also show in new [Figure 4--figure supplement 3](#fig4s3){ref-type="fig"}, that CLR01 is far less cytotoxic than various detergents, including Triton X-100, SDS, or N9. The tweezer also has been tested *in vivo* in multiple experiments, as mentioned above, and was found to have a high safety margin in mice ([@bib4]). As recommended, we now discuss possible mechanisms of membrane disruption in the revised Discussion. Finally, it is important to note that the HIV membrane possesses a highly unusual lipid composition, which is distinct even from the detergent-resistant microdomains typically found in the plasma membrane, indicating that HIV budding involves a specific lipid raft clustering process ([@bib8]). For example, although the HIV membrane resembles lipid raft microdomains in that it is enriched for saturated lipids, phosphatidylserine, plasmalogen-phosphatidylethanolamine, cholesterol, and sphingolipids, it is unusually enriched for the unusual sphingolipid dihydrosphingomyelin ([@bib8]; [@bib38]). This unusual lipid raft composition could make the viral membrane uniquely susceptible to the action of CLR01. In our future work, we intend to address this interesting point in greater detail.

*6) What is the CMC equivalent of CLR01? In other words, at what concentration does it form micro-aggregates or micelles? Some (perhaps many?) of the observed activities could be a result of non-specific activities, as described by the Shoicet group. DLS studies and detergent competition experiments need to be performed*.

As outlined in detail in the response to the editor, we performed a series of experiments to exclude that CLR01 forms detergent-like micelles or colloidal aggregates. Thus, we show that even at millimolar concentrations the tweezers are present as predominantly monomeric species; only in PBS buffer does a very weak dimerization occur and minute amounts of higher-order species can be observed by DLS, due to the strong bias of this technique for large particles. No cmc could be determined using pyrene fluorescence. These experiments are summarized in the new [Figure 7](#fig7){ref-type="fig"}. We have also performed a series of experiments to exclude the possibility that the minute quantities of higher order CLR01 structures are the active species, i.e.: CLR01 activity is not affected by BSA (which would adsorb to the colloid and quench activity) or by preclearing any colloidal aggregates by centrifugation ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5--figure supplement 2, 3, and 4](#fig5s2 fig5s3 fig5s4){ref-type="fig"}). Likewise, CLR01 is highly active in the presence of FCS ([Figure 4E, 8A-C](#fig4 fig8){ref-type="fig"}) and semen ([Figure 9B](#fig9){ref-type="fig"}), complex multiprotein mixtures that would also be predicted to quench the non-specific activity of colloidal CLR01 aggregates. Unfortunately, we were unable to perform the suggested experiments with non-ionic detergents as these exerted inhibitory effects on amyloidogenesis by seminal peptides, which conflated analysis. A similar issue of detergent incompatibility with amyloid assembly was encountered by Feng et al. ([@bib14]).

Reviewer \#3:

*\[...\] The manuscript could have substantial impact. Before it is published, I suggest the authors address the following concerns*:

*1) My major concern regards the mechanism of action. The authors postulate that classic host-guest complexes are forming with the cationic amino acids, as shown in* [*Figure 1B*](#fig1){ref-type="fig"}*, and this is important to the specificity and ultimate usefulness of the compounds. Currently, however, the manuscript lacks two controls that would help establish this mechanism*:

*A) First, the authors should control for colloidal aggregation on the part of the CLR01 itself. Colloidal aggregation of organic small molecules can disrupt protein fibrils, by protein sequestration in the small molecule colloid (Feng et al., Nature Chem. Biol., 2008). Such a mechanism must be controlled for, especially given the peculiar efficacy of the compounds against the virion membranes themselves (this is hard to square with a host-guest type interaction, but would make sense for colloidal aggregates). To do so, the authors should do one or more of the following i. Look to see if CLR01 is forming colloids in the 10 - 30 μM range, for instance by dynamic light scattering. ii. Add a mild, non-ionic detergent such as Tween-100 to disrupt the colloidal aggregates. This would right-shift the efficacy curves (assuming the detergent doesn\'t disrupt the fibrils directly). iii. Before addition to the fibrils, spin down the aqueous "solution" of CRL01 (not the DMSO one) in a microfuge at its highest speed for 20 minutes. Use the supernatant as the CLR01 solution for efficacy testing (colloids will typically pellet over this time). iv. Add 10 mg/ml BSA to the fibril mixture, before addition of CLR01. BSA will prophylacticly coat colloids, disrupting their actions*.

As outlined above in the response to editor, we now provide evidence that CLR01 is not functioning through colloidal aggregate formation. Thus, CLR01 is predominantly monomeric and only forms minute quantities of colloidal aggregates in PBS buffer, and does not form them at all in HEPES buffer ([Figure 7](#fig7){ref-type="fig"}). Even then, CLR01 activity is unaffected by BSA or by preclearing aqueous solutions of CLR01 (incidentally, stock CLR01 solutions were made in water or PBS and not DMSO, p. 23) via centrifugation ([Figure 2--figure supplement 4](#fig2s4){ref-type="fig"}; [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 5--figure supplement 2, 3, and 4](#fig5s2 fig5s3 fig5s4){ref-type="fig"}), indicating that even if present, colloidal CLR01 particles cannot be the active species. Unfortunately, we were unable to perform the suggested experiments with non-ionic detergents as these exerted inhibitory effects on amyloidogenesis by seminal peptides, which conflated analysis. A similar issue of detergent incompatibility with amyloid assembly was encountered by Feng et al. ([@bib14]).

*B) Second, the authors should look to see if free lysine competes for CLR01 binding, disrupting its ability to act on the fibrils and the virions. If it does not, or the effect is small, this would cast doubt on the mechanism proposed by the authors. This to me is an obvious control, and I worry that it was in the manuscript and I just overlooked it -- if I did I apologize. If not, it should be done*.

*Both controls should be done for both the effects on the protein fibrils and on the direct effects of the virus membrane. Whereas I hesitate to put authors to more work, I believe that these controls will substantially strengthen the manuscript, and should take more than a few days to perform*.

As outlined above in the response to the editor, we performed these important controls. As expected from all previously published data on CLR01, we found that free lysine and poly-L-lysine abrogate the anti-amyloid and antiviral effects of CLR01 ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}; [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}; [Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}).

*2) Minor points*:

*A) I thought many of the dose response curves could be higher in quality, and should be re-done at better resolution*.

We have now included additional replicates and tested additional concentrations of CLR01 to improve the accuracy of our IC~50~ and EC~50~ measurements ([Figure 2D, E, F, L, 3G, H](#fig2 fig3){ref-type="fig"}).

*B) In the third paragraph of the subsection "CLR01 disaggregates preformed SEVI and PAP85-120 fibrils" the authors write that CLR01 acts sub-stoichiometrically. How do they know what the concentration of the relevant fibril species is? What is the stoichiometry*?

By substoichiometric we meant relative to peptide monomers not fibrils. We now clarify this point in the manuscript (subsection "CLR01 remodels preformed SEVI and PAP85-120 fibrils").

*C) In the Discussion, the authors speculate on the use of CLR01 in vivo, as a drug or drug lead. Probably the only way such a molecule could be used is topically. It will not be orally absorbed (in all likelihood), and an intravenous route would lead to low compliance. If they are to speculate on this, as they do now, they should alert the readership to these points*.

Of course a topical application of CLR01 as microbicide is the only possible application, we hope that we have clarified this point in the revised manuscript (see first paragraph in the Discussion).

*D) I was unconvinced by the Concentration-Response curves, which are crucial to the efficacy arguments for CLR01. For* [*Figure 2D*](#fig2){ref-type="fig"}*, the curve should go through 0 (not 25%\...how is this possible at no compound?). More observations are needed in the transition region, and the authors should certainly sample every half-log, not every log10 in concentration*.

We have now adjusted our fits so the curves go through zero. We have now included additional replicates and tested additional concentrations of CLR01 to improve the accuracy of our IC~50~ and EC~50~ measurements ([Figure 2D, E, F, L, 3G, H](#fig2 fig3){ref-type="fig"}).

*For* [*Figure 2J*](#fig2){ref-type="fig"}*, they should calculate a curve that actually goes through their points. I assume they fixed the Hill coefficient to 1, which doesn\'t seem to be supported by the curve. Here too, they need more points*.

The reviewer is correct, we had fixed the Hill coefficient to 1. We now fit with a variable slope and have included additional replicates and tested additional concentrations of CLR01 to improve the accuracy of our IC~50~ measurement in [Figure 2L](#fig2){ref-type="fig"}.

*In* [*Figure 5*](#fig5){ref-type="fig"}*, the Y-axis of the concentration-response curves should be on a linear scale, not a log scale. If it were, the reader would quickly notice that the curves are quite steep, which can be informative, and sometimes concerning*.

As exemplified by [Figure 5A](#fig5){ref-type="fig"}, a semi-log representation does not provide more information, also with respect to the steepness of the curves. As we published all our research on antivirals as log-log diagrams e.g. Zirafi et al. ([@bib96]; Zirafi et al., 2015), we would prefer (if possible) to keep the figures in their original log-log representation.10.7554/eLife.05397.032Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.05397.032](10.7554/eLife.05397.032)

[^1]: These authors contributed equally to this work.
